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Abstract 
Nonalcoholic fatty liver disease (NAFLD) is a constellation of diseases ranging 
from hepatic steatosis to fibrosis, cirrhosis and potentially liver-related mortality. 
Estimates indicate that NAFLD affects 80-90% of obese individuals. No validated 
treatments exist for NAFLD beyond weight loss and lifestyle modifications, but these 
approaches have poor long-term adherence. This indicates a need to validate effective 
therapies that prevent the progression of NAFLD. Oxidative stress potentiates fibrosis by 
activating hepatic stellate cells (HSCs), which in turn deposit hepatic collagen. Consistent 
with earlier findings suggesting that green tea extract (GTE) mitigates hepatic steatosis 
and oxidative stress, we hypothesized that GTE would attenuate the fibrosis associated 
with NAFLD. Wistar rats (n = 63) were fed a low-fat diet (LFD) containing no GTE or 
high-fat diet (HFD) containing GTE at 0, 1 or 2% GTE for 8 wk. Fibrosis was visualized 
by Gomori’s trichrome stain and corroborated by measuring the collagen marker 
hydroxyproline (HYP). α-Smooth muscle actin (α-SMA), an indicator of HSC activation, 
and nuclear KLF6 protein were measured by western blot. Rats in the HFD group had 
histologic evidence of fibrosis and greater HYP than rats fed the LFD. Rats fed GTE at 
either level had little or no visible evidence of fibrosis and HYP levels were normalized 
to the extent of LFD controls. Rats fed the HFD had greater hepatic α-SMA expression 
compared to the LFD group whereas α-SMA in the HFD + 2% GTE group was not 
different from the LFD group. The HFD increased nuclear KLF6 accumulation relative to 
the LFD group, but was unaffected by GTE. α-SMA and HYP were correlated with 
serum AST and inversely related to hepatic total glutathione, suggesting that liver injury 
mediated by oxidative stress contributes to fibrosis. Collectively, these data indicate that 
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GTE protects against HFD-induced fibrosis by preventing HSCs activation and collagen 
deposition through a mechanism independent of the transcription factor KLF6. 
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Chapter 1: Introduction 
Nonalcoholic fatty liver disease (NAFLD) is a constellation of diseases that 
progress from relatively benign steatosis to nonalcoholic steatohepatitis (NASH), 
fibrosis, cirrhosis, hepatocellular carcinoma and eventually liver-related mortality [1]. 
NAFLD is estimated to affect 10-30% of Americans [2] and is closely associated with 
obesity with estimates indicating that 80-90% of obese individuals are afflicted with this 
disorder [3]. It is estimated that one-third of individuals with steatosis will develop 
NASH, and in turn, 33% of those individuals will develop fibrosis and 15% will develop 
cirrhosis [4]. There is no validated treatment for NAFLD beyond weight loss and co-
morbidity management and lifestyle modification [5], but  these interventions have poor 
long term adherence [6]. This necessitates the identification of both a simple and 
effective therapy aimed at preventing the progression of this disease. 
The development of NASH is most frequently described by the "two-hit" 
mechanism [7]. Liver steatosis is the "first hit" and encompasses metabolic disruptions 
associated with obesity. These disruptions, such as insulin or leptin resistance, cause 
excessive accumulation of fat in the liver [7]. Hepatic steatosis increases the vulnerability 
of the liver to a "second hit" in the form of lipid peroxidation initiated by oxidative stress, 
resulting from a number of factors including mitochondrial dysfunction, microsomal 
oxidation of fatty acids, and inflammatory cell infiltration [5]. 
Oxidative stress and inflammation associated with NASH induce hepatic stellate 
cell (HSC) activation. Activated HSCs adopt a myofibroblastic phenotype characterized 
by expression of α-smooth muscle actin (α-SMA) [1, 8] and begin producing 
extracellular matrix (ECM) proteins [1]. Once activated, HSCs also begin expressing 
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inflammatory cytokines and fibrogenic cytokines. This signaling cascade exacerbates 
inflammation and oxidative stress and results in fibrosis [1]. 
A transcription factor Kruppel-like factor 6 (KLF6) has been identified in carbon 
tetrachloride (CCl4) and methionine and choline deficiency models of hepatic fibrosis but 
not in simple steatosis [9]. mRNA levels of this transcription factor are modulated by 
oxidative stress [9] and KLF6 promotes the expression of several important pro-
fibrogenic proteins such as procollagen(α1)I [10, 11]. The mechanism by which KLF6 is 
activated and translocated into the nucleus has not yet been elucidated. However, during 
hepatic fibrosis KLF6 is localized in the nuclear and perinuclear area suggesting that 
nuclear translocation occurs during this process [11].  
Because oxidative stress and inflammation promote the progression of steatosis to 
fibrosis, it is logical that dietary approaches that counter oxidative stress and 
inflammation may prevent fibrogenesis. The bioactive components of green tea 
(Camellia sinensis) have hypolipidemic [12], anti-inflammatory [13] and antioxidant [14] 
properties. Furthermore, epidemiological studies suggest that there is in an inverse 
association between green tea consumption and all-cause mortality and mortality due to 
cardiovascular disease [15] and that consuming >10 cups/d may protect against liver 
injury [16]. 
Previous work in our lab has defined a diet-induced obese model of NASH in rats, 
the consequences of which are mitigated by green tea extract (GTE).  Our group has 
determined that rats consuming 60% of energy from fat for 8 wk have significant 
increases in hepatic levels of the inflammatory cytokines tumor necrosis factor-α (TNF-
α) and monocyte chemoattractant protein-1 (MCP-1) as well as increased nuclear binding 
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of the pro-inflammatory transcriptional factor nuclear factor-κB (NFκB). Additionally, 
hepatic glutathione (GSH) in these animals was depleted, indicating increased oxidative 
stress. When rats were provided with the GTE equivalent to 7-14 cups/day in humans in 
addition to the high-fat diet (HFD), they had significantly lower concentrations of the 
previously mentioned biomarkers for inflammation and maintained GSH status [13]. 
Since previous reports indicate that rats consuming a diet of 30% energy from fat for 12 
weeks develop NASH and fibrosis [17, 18], it is hypothesized that this model of NASH 
will also develop fibrosis.  
The central hypothesis of this thesis is that GTE will protect against fibrosis in a 
HFD-induced model of NAFLD. It is hypothesized that this effect will be accompanied 
by decreased HSC activation, since HSCs are activated via inflammatory signaling and 
oxidative stress and GTE has antioxidant and anti-inflammatory properties. It is also 
hypothesized that GTE will decrease KLF6 nuclear protein because of its antioxidant 
properties. To test these hypotheses, the following objectives were completed.  
o Objective 1: Define to what extent GTE prevents fibrosis associated with high-
fat feeding. To visualize fibrosis, liver tissue was stained with Gomori’s 
trichrome, which differentiates connective tissue from cytoplasm and nuclei. 
To quantify hepatic collagen accumulation, hepatic hydroxyproline 
concentration was measured as an indirect indicator of hepatic collagen 
deposition. 
o Objective 2: Define to what extent GTE prevents HSC activation associated 
with high-fat feeding. To test this hypothesis, hepatic protein expression of α-
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SMA, a protein expressed by HSCs, was measured by western blot and 
subsequent densitometry. 
o Objective 3: Define to what extent GTE prevents nuclear protein 
accumulation of KLF6. To test this hypothesis, nuclear extracts were prepared 
from liver homogenate and KLF6 protein accumulation was analyzed via 
western blot and subsequent densitometry.  
When studies from this thesis are completed, it is expected that rats fed a diet 
containing 60% energy from fat for 8 wk will develop hepatic fibrosis. It is also expected 
that feeding rats the GTE equivalent to 7-14 cups of green tea per day in humans in 
addition to the HFD will mitigate fibrosis and hepatic collagen deposition and that this 
will be accompanied by decreased HSC activation. It is expected that the findings in this 
thesis will support the investigation of increasing green tea consumption in humans as a 
strategy for preventing fibrosis associated with NAFLD. 
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Chapter 2: Review of Literature 
2.1 Introduction 
 Steatosis potentiates the development of nonalcoholic steatohepatitis (NASH) and 
fibrosis. These conditions are referred to as nonalcoholic fatty liver disease (NAFLD) and 
increase liver-related morbidity and mortality. Oxidative stress plays an important role in 
disease progression from steatosis to fibrosis.  Thus, therapies aimed at reducing 
oxidative stress in the liver may play a role in reducing progression of NAFLD. This 
literature review will introduce the prevalence of NAFLD and its diagnosis, then discuss 
the etiology of steatosis, NASH and fibrosis in the context of obesity. Next, various diet-
induced animal studies of NAFLD will be discussed to support diet-induced obesity as a 
model of fibrosis. Lastly, since this thesis project is examining GTE as a novel strategy to 
regulate fibrosis, a discussion of the hepatoprotective properties of green tea will be 
provided.  
2.2 Epidemiology of NAFLD 
At present, it is estimated that between 10-30% of Americans have some stage of 
NAFLD [2]. NAFLD begins with fat accumulation in the liver otherwise known as 
steatosis [7]. It is estimated that one-third of those with simple steatosis will develop 
NASH. Of those who develop NASH, 33% will develop fibrosis and 15% will develop 
cirrhosis [4]. Several independent predictors for disease progression into fibrosis have 
been identified, such as elevated fasting blood glucose, decreased insulin sensitivity [19] 
and elevated body mass index (BMI) [20]. Data from NHANES III indicates that 
individuals with NAFLD have greater liver-related mortality than individuals who do not 
have NAFLD [21]. Among individuals with NAFLD, liver disease was the third leading 
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cause of death [21]. For comparison, liver disease was the 11th leading cause of death 
among individuals without NAFLD [21]. Taken together, these data suggest that NAFLD 
increases liver-related morbidity and mortality.  
One of the challenges in identifying the rates of NAFLD in the population is the 
difficulty in diagnosing the condition. The gold standard for diagnosing NAFLD is liver 
biopsy, however this procedure is quite invasive [1]. Ultrasonography can also be used. 
Ultrasonography has a sensitivity of 89% and a specificity of 93% in detecting steatosis 
and a sensitivity of 77% and a specificity 89% in detecting the stage of fibrosis [22]. The 
simplest technique for identifying potential cases of NAFLD is blood testing for the liver 
transaminases aspartate aminotransferase (AST) and alanine aminotransferase (ALT), but 
NAFLD can be present in as many as 50% of individuals that do not have elevated liver 
enzymes [3]. The sensitivity of ALT alone in detecting NAFLD is 45% [23]. The positive 
predictive value for using both AST and ALT to diagnose NAFLD is 90% while it is 34% 
for diagnosing NASH [23]. ALT is an enzyme that resides primarily in hepatocyte 
cytoplasm, while AST resides primarily in hepatocyte mitochondria [24]. For this reason 
ALT is often considered a more reliable biomarker for hepatocyte injury than AST. 
However, research on the use of AST alone as diagnostic criteria for extensive liver 
injury suggests that it may be more useful than ALT in determining the degree of 
necroinflammation [25] and liver damage [26]. Brunt et al [25] report that mean AST 
levels were higher in NAFLD patients with severe histological scoring of 
necroinflammation compared to the AST levels measured in those with mild or moderate 
scoring (P < 0.002, P < 0.05) while there were no differences between ALT values and 
disease severity (P > 0.05). Additionally, multivariate stepwise regression analyses of 
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various predictors of histological damage to the liver indicated AST values were the most 
important predictive variable of histological activity (r = 0.62) in patients with the hepatic 
C virus. [26].  One hypothesis for this suggests that as degree of liver injury increases, the 
degree of mitochondrial damage increases which thus increases blood levels of AST [26].  
The provided specificities and positive predictive values indicate that serum 
aminotransferases and ultrasonography underestimate the prevalence of NAFLD. 
Because simple steatosis can develop into fibrosis [1], preventative measures should be 
taken in individuals at risk for NAFLD. At present, there is no validated treatment of 
NAFLD besides weight loss and lifestyle intervention, however these treatments have 
low compliance [6]. This necessitates the identification of simple dietary interventions 
that can prevent the progression of NAFLD.    
2.3 Development of Steatosis 
Steatosis, or fat accumulation in the liver, is the initial stage of NAFLD and is 
often referred to as the “first hit” leading to NASH and fibrosis [7]. Histologically, grade 
one of steatosis is diagnosed when <33% of hepatocytes are affected, the second grade is 
diagnosed when between 33-66% of hepatocytes are affected and the third grade is 
diagnosed when >66% of hepatocytes are affected [5].  Thus, interventions aimed at 
preventing steatosis may be successful in limiting the progression of NAFLD.  
Obesity plays a significant role in developing steatosis since it potentiates the 
development of insulin resistance and type II diabetes [27]. In fact, the prevalence of 
NAFLD is between 80–90% in obese adults and between 30–50% in patients with type II 
diabetes [3]. The mechanisms behind the development of steatosis from obesity and 
diabetes will be explained in the following paragraphs. 
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2.3.1 Obesity 
Obesity leads to macrophage infiltration of adipose tissue, which results in 
increased inflammatory signaling [28]. Microarray analysis performed on white adipose 
tissue from ob/ob mice indicated that 59% of all of the genes that were upregulated more 
than 2-fold over the lean control could be classified as inflammation-related genes. The 
remaining genes were related to other diverse molecular pathways such as fat storage, 
cholesterol metabolism or cell division. Histological staining of the adipose tissue 
indicated that tissue from ob/ob mice had significant macrophage infiltration compared to 
the lean control. The adipose tissue from ob/ob mice was also separated into its adipocyte 
and stromal-vascular fractions. Analysis of mRNA in these tissue fractions indicated that 
the stromal-vascular fraction expressed significantly greater mRNA for tumor necrosis 
factor-α (TNF-α) [29]. These results suggest that macrophage infiltration of adipocytes in 
obese mice leads to increased expression of the pro-inflammatory cytokine TNF-α. This 
hypothesis is supported by observations in humans. Explanted adipose tissue from obese 
post-menopausal women (BMI > 25) produced significantly greater TNF-α mRNA and 
protein compared to biopsied tissue from lean controls (BMI < 25). There was also a 
significant positive correlation (r = 0.82) between TNF-α mRNA production by adipose 
tissue and plasma insulin levels indicating that greater TNF-α expression from adipose 
tissue correlates to reduced insulin sensitivity [30]. Thus, obesity increases systemic 
inflammation and contributes to insulin resistance which can lead to hepatic steatosis.   
2.3.2 Insulin Resistance  
The pro-inflammatory cytokine TNF-α is increased in obese individuals and 
correlates with insulin sensitivity [30]. TNF-α interferes with the signaling cascade 
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downstream of the insulin receptor resulting in insulin resistance [30]. When insulin 
binds to the insulin receptor, the insulin receptor phosphorylates insulin receptor 
substrate-1 (IRS-1) on its tyrosine residue. In adipose and muscle tissue, however, IRS-1 
is phosphorylated on a serine residue in response to stressors, including TNF-α. IRS-1 
phosphorylated at this location does not respond to the insulin receptor [28]. Treatment of 
adipocytes with 2.5 ng/ml of TNF-α resulted in decreased phosphorylation of IRS-1 on 
the tyrosine residue [31]. This interruption in the signaling cascade has direct effects on 
the levels of glucose in the blood as the glucose transporter type 4 is no longer 
translocated to the cell surface [31]. Excessive blood glucose that results from decreased 
insulin sensitivity leads to a greater release of insulin by pancreatic β-cells and eventually 
leads to an excess of blood insulin, termed hyperinsulinemia [32].  
2.3.3 Steatosis 
Elevated blood insulin contributes to steatosis by increasing de novo lipogenesis. 
When isolated hepatocytes from rats treated with streptozotocin to induce diabetes were 
treated with insulin in vitro, the result was an in increase in sterol regulatory element 
binding protein-1c (SREBP-1c) mRNA levels and nuclear protein levels of this 
transcription factor [33]. Additionally, hyperinsulinemic ob/ob mice expressed greater 
hepatic SREBP-1c mRNA in addition to mRNA of its downstream target genes, fatty 
acid synthase and acetyl-CoA carboxylase [34]. This presents a paradox in that during 
insulin resistance, the liver is still selectively responsive to insulin.  
The liver displays selective insulin sensitivity due to its differential response to 
TNF-α. Insulin resistant adipose tissue and muscle tissue taken from obese Zucker rats 
had reduced insulin receptor tyrosine phosphorylation of IRS-1. However, no significant 
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changes were observed in insulin-stimulated tyrosine phosphorylation of IRS-1 in hepatic 
tissue from these animals [35]. This suggests that TNF-α does not mediate hepatic insulin 
resistance in the same way as it does in muscle or adipose tissue. During selective hepatic 
insulin resistance, insulin fails to suppress gluconeogenic enzymes such as 
phosphoenolpyruvate carboxykinase or glucose-6-phosphatase, yet it increases 
transcription and nuclear translocation of SREBP-1c which upregulates genes associated 
with de novo lipogenesis [36]. The reason for this is bifurcation of the insulin signaling 
pathway downstream of the kinase Akt [37]. Inhibition of Akt augments gluconeogenic 
gene expression and reduces SREBP-1c upregulation of lipogenic gene expression. In 
contrast, inhibition of a kinase downstream of Akt, mammalian target of rapamycin 
complex 1, results in augmented gluconeogenic genes and increased SREBP-1c 
upregulation of lipogenic genes, the characteristic insulin response seen in type 2 diabetes 
[37].  Thus, hyperinsulinemia and selective hepatic insulin resistance contributes to 
enhanced lipogenesis.  
Besides increasing de novo lipogenesis, SREBP-1c contributes to steatosis by 
decreasing β-oxidation. SREBP-1c upregulates acetyl-CoA carboxylase. Acetyl-CoA 
carboxylase adds a carboxyl group to acetyl-CoA, resulting in the formation of malonyl-
CoA. Malonyl-CoA is an inhibitor of the enzyme carnitine palmitoyl transferase-1. 
Carnitine palmitoyl transferase-1shuttles fatty acids into the mitochondria for β-oxidation 
[38]. Thus, upregulation of acetyl-CoA carboxylase by SREBP-1c during insulin 
resistance contributes to hepatic steatosis by inhibiting β-oxidation of fatty acids.  
 Insulin resistance also leads to steatosis by increasing circulating free fatty acids . 
Insulin suppresses the activity of the enzyme hormone sensitive lipase in insulin sensitive 
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individuals, however insulin resistance increases its activity. Since hormone sensitive 
lipase is responsible for lipolysis in adipose tissue, insulin resistant adipose tissue 
releases excess free fatty acids into the blood [39]. Insulin resistant hepatocytes then 
uptake these free fatty acids [5], contributing to steatosis.  
2.4 Development of NASH 
Histologically, NASH is diagnosed when steatosis involves more than 66% of 
hepatic lobules, ballooning hepatocytes are observed indicating hepatocellular damage, 
and there is mild infiltration of the hepatic lobules by polymorphonuclear and 
mononuclear cells, indicating the presence of inflammation [5].  Fat accumulation in the 
liver does not always lead to necroinflammation and progression of NASH or fibrosis. 
This prompted the suggestion of oxidative stress as the “second hit” involved in the 
pathogenesis of NAFLD [7]. Oxidative stress initiates lipid peroxidation in the lipid-
laden steatotic liver, leading to cellular damage and inflammation [27]. Therapies aimed 
at mitigating oxidative stress may therefore be successful in limiting the progression of 
steatosis to fibrosis. The sources and consequences of oxidative stress are introduced 
below.   
2.4.1 Sources of Oxidative Stress 
The mitochondria are one source of oxidative stress in the liver during NAFLD. 
Hepatic fatty acids are metabolized via mitochondrial β-oxidation which, under 
conditions associated with NAFLD, generates greater reactive oxygen species (ROS). 
Mitochondria isolated from ob/ob mice produced superoxide anions at a greater rate than 
mitochondria isolated from control mice, indicating a role for obesity in hepatic 
mitochondrial dysfunction [40].  This process may be initiated by the pro-inflammatory 
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cytokine TNF-α, since cells cultured with TNF-α have been shown to inhibit 
mitochondrial electron transport chain activity [41]. As a result of continued metabolism 
under these conditions, there is over-reduction of the electron transport chain which leads 
to leakage of the superoxide anion [42]. Thus, obesity and inflammation result in greater 
hepatic oxidative stress and contribute to the second hit of NASH.  
Other sources of hepatic oxidative stress in NAFLD are cytochrome P450 
enzymes, more specifically, cytochrome P4502E1 (CYP2E1) and cytochrome P4504A 
(CYP4A). These cytochrome P450 enzymes are located in the endoplasmic reticulum of 
hepatocytes and the primary function of these cytochrome P450 enzymes is to detoxify 
lipophilic compounds by hydroxylation [43]. CYP2E1 is upregulated during hepatic 
insulin resistance [44] and free fatty acid accumulation in the liver upregulates CYP4A 
[45]. Cytochrome P450 enzymes require electrons to be donated by the enzyme 
nicotinamide adenine dinucleotide phosphate (NADPH)-cytochrome P450 reductase to 
complete hydroxylation, but the activities of these 2 enzymes are poorly coupled, 
resulting in the generation of superoxide [43]. Peroxisomal β-oxidation of excess fatty 
acids also contributes to hepatic oxidative stress. In the initial step of peroxisomal β-
oxidation, H2O2 is formed by the action of acyl-CoA oxidase, which donates electrons 
directly to molecular oxygen [38]. Free fatty acids induce transcription of acyl-coA 
oxidase [46] and increase peroxisomal β-oxidation and production of H2O2 [38]. Thus, 
induction of CYP2E1 and CYP4A in addition to peroxisomal β-oxidation in the steatotic 
liver generates oxidative stress [47].  
Another source of oxidative stress in the liver is apoptotic hepatocytes. Biopsies 
from individuals with NASH showed 2.7-fold increase in histological staining for the 
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death receptor tumor necrosis factor receptor-1 (TNF-R1) compared to biopsies from 
healthy individuals, and staining intensity for TNF-R1 correlated to disease severity [48]. 
TNF-α binding to TNF-R1 initiates apoptosis by inducing DNA fragmentation [49] and 
the release of ROS from the mitochondria [40]. Furthermore, apoptotic hepatocytes 
release pro-inflammatory mediators, which attracts Kupffer cells and neutrophils [1]. In 
an inflammatory environment, these cells of the immune system produce superoxide 
anions through NADPH-oxidase in a phenomenon referred to as “oxidative burst” [50]. 
Thus hepatocyte apoptosis leads to direct release of ROS into the environment from the 
mitochondria during apoptosis and initiates immune cell infiltration of the liver which 
also contributes to the release of ROS in the pathogenesis of NASH.   
2.4.2 Consequences of Oxidative Stress 
Oxidative stress from the above sources leads to lipid peroxidation, which further 
contributes to the hepatic damage observed in NASH [27]. Lipid peroxidation is the 
process by which lipids are converted to lipid hydroperoxides by the oxidation of a 
polyunsaturated fatty acid by oxidants such as superoxide or hydroxyl radicals [51]. The 
formation of lipid hydroperoxides potentiates the formation of additional lipid 
peroxidation through the formation of the lipid radical [51]. Lipid peroxidation can 
directly damage cell membranes which results in loss of membrane fluidity and 
eventually leading to necrosis [27]. Additionally, lipid peroxidation of the phospholipid-
rich mitochondria can further lead to mitochondrial dysfunction and release of  ROS into 
the environment [38]. Lipid hydroperoxides are also detrimental in that they auto-oxidize 
to form the cytotoxic molecules 4-hydroxynonenal (4-HNE) and malondialdehyde 
(MDA) [52] which are harmful in that they bind to mitochondrial DNA [53], nuclear 
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DNA [54] and proteins [55], which may initiate the immune response or inactivate 
important enzymes [27]. Because the steatotic liver contains an excess of lipids, it is 
especially prone to the harmful effects of the lipid peroxidation [7].  
Lipid peroxidation also contributes directly to steatosis. The lipid peroxidation 
end products thiobarbituric acid reactive substrates (TBARS) are associated with 
increased post-ER presecretory proteolysis of ApoB100 [56]. Incubation of hepatocytes 
with ω-6 and ω-3 polyunsaturated fatty acids increased ApoB100 degradation via 
intracellular induction of TBARSs and this effect was not observed when the antioxidant 
vitamin E was added to the media [56]. Thus, oxidative stress limits very low density 
lipoprotein secretion by the liver and increases fat accumulation in the liver.  
2.5 Development of Fibrosis  
2.5.1 Overview 
Taken together, all of the causes and consequences of steatosis and NASH lead to 
hepatic damage and initiate the process of fibrogenesis [1]. Fibrogenesis begins with the 
activation of HSCs [27]. In the healthy liver, HSCs constitute less than 10% of total 
resident cell population and reside in the space of Disse between the sinusoidal 
endothelium and the hepatocyte chords within the liver lobule (Figure 2.1A) [57]. Once 
activated, HSCs increase in number and adopt a myofibroblastic phenotype and express 
the structural protein α-smooth muscle actin (α-SMA). With this new phenotype, HSCs 
begin to produce pro-inflammatory and pro-fibrogenic cytokines. Activated HSCs are 
also the primary source of ECM components deposited during fibrosis [58], and by 
reducing HSC activation, it may be possible to prevent fibrosis.  
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Fibrosis is defined as the remodeling of the ECM to contain primarily type I 
collagen [1]. In the healthy liver, the ECM provides a low-density barrier between the 
sinusoids and the cords of hepatocytes (Figure 2.1A). The low density of this barrier, in 
addition to the porous arrangement of endothelial cells, allows free exchange between 
liver cells and blood flow [59]. Changes in the ECM brought on by fibrogenesis in the 
perisinusoidal space interrupt blood flow to the hepatocytes [60]. Under fibrogenic 
conditions, the quantity of ECM components can increase 3-5 fold, with a shift towards a 
composition of primarily the fibrillar collagens type I and III and away from lower-
density collagen type IV [57]. This process is referred to as sinusoidal capillarization and 
results in further hepatocyte dysfunction and portal hypertension due to decreased blood 
flow to the hepatocytes. Thus, fibrosis contributes the advanced diseases cirrhosis and 
hepatocellular carcinoma [60]. The etiology of the liver injury dictates where fibrogenesis 
begins, and in the case of NAFLD, fibrosis begins in the pericellular and perisinusoidal 
space in zone III of the liver lobule [25] (Figure 2.1B).  
2.5.2 Causes of Fibrosis  
Oxidative stress activates HSCs, thereby linking the second hit of NASH to 
fibrogenesis. When quiescent HSCs were incubated with ROS-generating CYP2E1-
overexpressing HepG2 cells, they expressed more α-SMA compared to HSCs incubated 
with control HepG2 cells. This suggests greater HSC activation is a result of an 
environment containing greater ROS. HSCs also expressed more intracellular and 
secreted collagen type I protein than HSCs incubated with conventional HepG2 cells. 
This effect was abrogated by the addition of vitamin E or catalase to the co-culture. [61]. 
Additionally, human HSCs incubated directly with the lipid peroxidation product 4-HNE 
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produced more procollagen(α1)I mRNA and type I collagen protein compared to control 
culture [62].  
Fibrosis is also associated with the second hit of NASH through greater Kupffer 
cell activity. In NASH, Kupffer cells release the cytokines TNF-α and transforming 
growth factor β1 (TGFβ1). TNF-α promotes the inflammatory response and activates 
HSCs [1]. Activation of inhibitor of nuclear factor-κB kinase subunit-β (IKK-β) by TNF-
α induces nuclear translocation of the transcription factor nuclear factor-κB (NFκB). 
NFκB nuclear activity upregulates monocyte chemoattractant protein-1 (MCP-1) [63] and 
TNF-α expression [64]. Thus, TNF-α activation of NFκB further promotes insulin 
resistance and the inflammatory response. Additionally, it has been shown that incubation 
of TNF-α with HSCs increases the transcription of TGFβ1 receptor type I [65] and in this 
way promotes the pro-fibrogenic response in addition to its pro-inflammatory effect.   
TGFβ1 is responsible for the pro-fibrogenic response in HSCs by promoting the 
transcription of various ECM proteins, including the most prevalent collagen in fibrosis, 
collagen type I. TGFβ1 increases expression of the procollagen(α1)I gene in HSC by 
promoting the formation of H2O2. Accumulation of intracellular H2O2 stimulates 
expression of the p35 isoform of CCAAT/enhancer-binding protein-β (C/EBPβ) and 
promotes binding of this factor to a TGFβ1 responsive element located the 
procollagen(α1)I gene promoter [66].  To promote further fiber accumulation, TGFβ1 
also induces the expression of the collagenase inhibitor, tissue inhibitor of matrix 
metalloproteinases-1 [67].  
Additionally, TGFβ1 promotes fibrosis by increasing HSC proliferation. The 
principle mitogen for HSC is platelet-derived growth factor (PDGF) [68], which is 
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expressed by activated Kupffer cells in damaged liver [69]. TGFβ1 receptor binding 
increases expression of β-type platelet derived growth factor receptor (PDGF-Rβ) [67] 
and in this way facilitates HSC proliferation and promotes fibrogenesis. NFκB has also 
been identified as a promoter of PDGF-Rβ expression [70]. This suggests a potential role 
for TNF-α, or other upstream activators of NFκB, in HSC proliferation. 
TGFβ1 is also responsible for propagating the pro-fibrogenic response by 
inducing further TGFβ1 production. Quiescent HSCs express low levels of TGFβ1 
receptors, while activated HSCs express more mRNA for TGFβ1 receptor type I and 
TGFβ1 receptor type II. This has been shown to be a direct result of TGFβ1 binding, 
which indicates that TGFβ1 propagates the pro-fibrogenic response in an autocrine 
manner [71]. Additionally, TGFβ1 signaling promotes the expression of intracellular α-
SMA via the Smad3 signaling pathway [72], indicating its involvement in changing the 
HSC phenotype.  
Direct consequences of obesity such as type II diabetes also play a role in HSC 
activation. HSCs express receptors for advanced glycation end products (AGE) which are 
elevated in diabetic individuals [73] and AGE receptor binding promotes HSC activation 
[74]. Also elevated in diabetic individuals is angiotensin type II. Angiotensin type I 
receptors bind to angiontensin type II and promote vasoconstriction in peripheral tissue. 
Angiotensin type I receptors are present on both quiescent and activated HSCs and 
angiotensin type I receptor binding by angiotensin type II stimulates ECM secretion, 
HSC proliferation, release of inflammatory cytokines, release of growth factors and 
inhibitors of collagen degradation [74].  
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Obese individuals also often develop leptin resistance and as a result have 
elevated blood leptin. The leptin deficient ob/ob model of NAFLD does not exhibit a 
fibrogenic phenotype, while repletion of leptin in this system allows for the disease 
progression into fibrosis [75]. This indicates that leptin is essential to the hepatic 
fibrogenic response. Leptin plays an role in fibrosis by modulating levels of free TGFβ1 
and it has been hypothesized that this may be due to increased transcription of urokinase-
like plasminogen activator, which is responsible for activating plasmin which frees 
TGFβ1 from its latency-associated peptide [75]. Leptin binding to its receptors also 
signals direct upregulation of TGFβ1 protein itself through the STAT3 and STAT5 
signaling pathway [76]. Leptin has also been shown to increase HSC expression of 
PDGF-Rβ [77] and thus increases HSC proliferation.  
The ECM also plays a role in activation of HSCs. Quiescent HSCs cultured on 
matrigel, a surface containing basement membrane components, maintain their quiescent 
phenotype. When cultured on polystyrene, a type I collagen coated dish or a type IV 
collagen coated dish, HSCs exhibited their activated phenotype [78, 79]. The 
environment also dictates how HSCs respond to external stimuli. When TGFβ1 was 
added to HSCs cultured on type I collagen-coated culture dishes, collagen synthesis of 
the cells grown on type I collagen-coated dishes was stimulated. Conversely, there was 
no response to TGFβ1 in terms of collagen synthesis by the HSCs grown on a dish coated 
in type IV collagen. Thus, the reaction of HSCs to cytokines is also modulated by ECM 
[80]. 
  A transcription factor that upregulates collagen during fibrosis is KLF6. In 1998, 
Vlad Ratziu and his colleagues [10] isolated HSCs from rats administered CCl4 and 
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identified the transcript for a molecule containing a zinc-finger motif, suggesting the 
presence of a novel transcription factor associated with hepatic injury. They further 
defined this molecule as the transcription factor Zf9 [10] which would later be named 
KLF6 because of its structural similarity to other proteins in the Kruppel-like factor 
family of transcription factors [81]. KLF6 is localized in the nuclear and perinuclear 
space in HSCs isolated from rats injected with CCl4 to induce liver injury, and in vivo 
expression and biosynthesis of this protein is increased in response to liver injury with 
CCl4 [11].  
These results prompted further research into identifying the target genes 
associated with this transcription factor. Ratziu et al [10, 11] have shown that KLF6 
upregulates the transcription of procollagen(α1)I as well as the pro-fibrogenic cytokine 
TGFβ1 and its receptors type I and II. Additionally, KLF6 increases transcription of 
urokinase-like plasminogen activator, a molecule that cleaves plasminogen to plasmin, 
whose role in fibrosis is to free TGFβ1 from its latency-associated peptide allowing it to 
bind to its receptors [82]. 
 Upregulation of KLF6 has been evidenced in CCl4-induced liver injury [11] and 
in the methionine choline deficient diet models of steatohepatitis [9]. However, KLF6 is 
not upregulated in simple steatosis [9]. One hypothesis suggests that KLF6 is upregulated 
in part by oxidative stress. Cardiac muscle cells treated with H2O2 had increased 
transcription of KLF6 [83]. Furthermore, HepG2 cells that overexpress CYP2E1 
generated H2O2 and O2• and had greater transcription of KLF6 when compared to control 
HepG2 cells. Incubation of the CYP2E1-overexpressing cells with the CYP2E1 substrate 
arachidonic acid increased KLF6 expression, while increased KLF6 was not observed 
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when arachidonic acid was added in addition to vitamin E [84]. Taken together, these 
data suggest that oxidative stress may be a mediator of KLF6 expression.  
2.6 High-Fat Diet-Induced Models of NASH and Fibrosis 
 When a HFD using lard as its fat source was used in a long term study of 48 wk, 
animals developed NASH that progressed into fibrosis [18].  Sprague Dawley rats were 
fed a HFD containing 30% energy from fat from lard and the control group was fed a 
lower-fat diet containing 10% energy from fat from lard. At week 4, rats in the 30% 
group developed hepatic steatosis and had greater liver mass compared to the control rats. 
At week 8, the rats fed 30% fat had elevated body mass, epididymal fat mass, serum free 
fatty acids, and serum protein concentration of TNF-α. At week 12, rats in the 30% group 
had histological evidence of inflammation and perisinusoidal fibrosis in addition to 
immunohistological staining of α-SMA and TGFβ1. At this time point, increased serum 
total cholesterol and serum ALT were also observed in the 30% fat group.  After week 
24, all of the rats had developed fibrosis which continued to develop through week 48 
[18].  This study confirms that a high-fat high-lard diet induces NASH and fibrosis and 
that this begins around week 12 of the dietary intervention.   
The aforementioned study provides a detailed framework for what occurs in an 
animal model fed a diet containing 30% energy from fat over an extensive period of 48 
weeks. Other researchers have experimented with different fat percentages and shorter 
study durations [17, 85, 86]. Several studies using different diet compositions have been 
completed using a 12-week time frame. Sprague Dawley rats were fed either a diet 
containing 10% energy from fat or a diet containing 30% energy from fat as lard for 12 
wk. The animals in the 30% group had an elevated number of Kupffer cells, indicating 
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greater inflammation. Perisinusoidal fibrosis was also observed, suggesting early stages 
of fibrosis [17] and these findings are consistent with the observation of Xu et al [18] 
described above. Mice fed a diet of 45% energy from fat as lard compared to diet of 10% 
energy from fat as lard for 12 wk had greater body mass, homeostatic model of insulin 
resistance (HOMA-IR), plasma ALT, plasma leptin and plasma free fatty acids. They 
also accumulated hepatic triglycerides and had histological evidence of steatosis. This 
study did not report on any parameters of fibrosis [85]. An even shorter study duration of 
8 wk comparing a diet of 10% energy from fat as lard to one of 60% energy from fat as 
lard found that mice fed 60% fat diet had increased body mass, adipose mass, plasma TG, 
plasma free fatty acids, plasma cholesterol and plasma ALT. Additionally, there was an 
elevation in hepatic TGs and hepatic free fatty acids and no data was reported regarding 
fibrosis [86]. Taken together, these  studies confirm that diets with energy percentage of 
30% or greater fed over a period of 12 weeks or less can also induce oxidative stress, 
inflammation, NASH and, as some authors report,  fibrosis.  
Previous work in the model used in this thesis indicates that feeding rats a 60% fat 
diet for 8 weeks results in increased body mass, adipose tissue mass,  serum AST, serum 
ALT, serum leptin and HOMA-IR compared to the low-fat diet control fed a diet of 10% 
energy from fat [13, 87]. Rats fed the 60% fat also had greater hepatic triglycerides, 
hepatic total lipids greater expression of pro-inflammatory cytokines and reduced hepatic 
total glutathione (tGSH) compared to the control [13], suggesting that this diet model 
develops NASH. Because similar diet interventions over 12 weeks have similar results 
with lower fat percentages and develop fibrosis, it was hypothesized that the model used 
by Park et al [13] would also develop fibrosis.   
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2.7 Green Tea  
At present, there is no validated treatment for NAFLD. Weight loss and co-
morbidity management and lifestyle modification can be effective [5], but these 
interventions have poor long-term adherence [6]. This necessitates the identification of 
both a simple and effective therapy aimed at preventing the progression of this disease.  
Several studies have indicated that green tea consumption has important 
mitigating effects on the components of metabolic syndrome [15, 16, 88-90]  and because 
the development of NAFLD is closely associated with components of metabolic 
syndrome, GTE may exhibit protective effects against NAFLD. In a randomized, double-
blind, placebo-controlled study, obese individuals having a BMI > 30 kg/m2 and without 
hypertension, diabetes, impaired glucose tolerance or a history of coronary artery disease, 
stroke or abnormal liver function were provided with a 379 mg GTE supplement or a 
placebo. After 3 months, patients in the green tea supplement group had significantly 
lower total cholesterol, serum triglycerides, low-density lipoprotein cholesterol and blood 
glucose compared to baseline. They also had significantly greater high-density 
lipoprotein cholesterol and blood total antioxidant status. Compared to the placebo group, 
patients given the GTE supplement had reduced BMI, waist circumference, total 
cholesterol and low-density lipoprotein cholesterol and had greater blood total 
antioxidant capacity [88] This study indicates that GTE can mitigate dyslipidemia and 
hyperglycemia associated with obesity, promote weight loss and improve systemic 
antioxidant status. Epidemiological studies also suggest that green tea may have 
important health-promoting properties. In a study of 13,000 Japanese adults, daily 
consumption of one cup of green tea was associated with a reduction in serum total 
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cholesterol [89]. Individuals consuming >6 cups per day of green tea were less likely to 
develop type II diabetes than those who drank <1 cup per day per wk [90] and 
consumption of green tea has been shown to be inversely associated with all-cause 
mortality and mortality due to cardiovascular disease [15]. Increased green tea 
consumption has also been shown to be associated with decreased serum triglycerides, 
increased high-density lipoprotein cholesterol and decreased low-density lipoprotein 
cholesterol [16]. Furthermore, the hypothesis that GTE may have hepatoprotective 
properties is supported by a cross-sectional study of 1,371 Japanese men in which 
consumption of >10 cups/day of green tea was associated with lower serum 
transaminases and thus decreased liver injury [16].  
2.7.1 Green Tea Composition and Bioavailability 
To analyze the hepatoprotective effects of the entire profile of green tea 
components, GTE is utilized. GTE is prepared from green tea infusion and contains four 
major catechins, epigallocatechin gallate (EGCG), epigallocatechin (EGC), epicatechin 
gallate (ECG) and epicatechin (EC). These catechins represent 30–42% of the solid 
weight of brewed tea [91]. Catechin composition of GTE is distributed as 48% EGCG, 
31% EGC, 13% ECG and 8% EC [92]. Green tea also contains the flavonols kaempferol, 
quercitin, and myricitin and together  they comprise between 0.5% - 2.5% of the solid 
weight of GTE [91]. GTE also contains between 2.5-4.5% caffeine by weight [93]. GTE 
can be purchased in powdered form which allows it to be mixed into animal diets without 
altering energy consumption [13]. 
Consumption of GTE was chosen over EGCG or intraperitoneal injection of 
catechins because of the differential bioavailability of green tea catechins. A 
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pharmacokinetic study analyzed plasma levels of EGCG, EGC and EC in 8 subjects. 
Subject were administered a single oral dose 20 mg/kg body weight of green tea solids 
dissolved in 200 ml water on three separate occasions. GTE contained 13.9% EGCG, 
11.0% EGCG and 3.2% EC by weight. The maximum plasma concentration of free plus 
conjugated catechins ( standard deviation) for EGCG were 77.9  22.2 ng/ml, for EGC 
it was 223.4  35.2 mg/ml and for EC it was 124.03   7.86 ng/ml. These values were 
observed between 1.3-1.6 h post ingestion. In the plasma, EGCG was mostly present in 
its free form, whereas EGC and EC were mostly in the glucuronidated conjugated form. 
Over 90% of the total urinary EGC and EC, almost all in the conjugated forms, were 
excreted after 8 hr. The quantity of 4-O-methyl EGC at levels higher than EGC was 
detected in the urine and plasma, indicating the use of this catechin as a substrate by 
catechol-O-methyl transferase [94].  This study indicates that the bioavailability of green 
tea catechins does not mirror the quantity ingested. EGCG was the most prevalent 
catechin in the GTE but it had the lowest peak plasma concentration. It also indicates that 
EGC and EC are more susceptible to phase II metabolism. These results should be 
considered when performing or interpreting experiments on isolated catechins of green 
tea and support the use of whole GTE in studies aiming to elucidate potential health 
benefits of increased green tea consumption. For this reason, this thesis investigated the 
effects of consuming GTE orally.  
2.7.2 Green Tea and Steatosis   
Previous work in our lab has shown that GTE can prevent the development of 
simple steatosis [95]. Ob/ob mice were fed a diet containing 0%, 1% or 2% GTE for 6 
wk. Animals fed either dose of GTE had less adipose mass, lower serum transaminases 
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and reduced plasma and hepatic triglycerides compared to the ob/ob control, and GTE 
dose-dependently decreased hepatic total lipids and mitigated histological evidence of 
hepatic steatosis [95]. In another study, ob/ob mice were provided a diet containing 0%, 
0.5% or 1% GTE for 6 wk [96]. It was observed that GTE at 1% reduced hepatic lipid 
content and serum free fatty acids. GTE also attenuated mRNA expression of SREBP-1c, 
fatty acid synthase, stearoyl-coA desaturase and hormone sensitive lipase in adipose 
tissue that was otherwise elevated in the ob/ob control. These data suggest that GTE 
suppresses adipose lipogenensis associated with SREBP-1c and lipolysis by hormone 
sensitive lipase, thereby decreasing adipose-derived free fatty acids available to the liver 
[96]. By reducing steatosis, the liver will be less susceptible to the lipid peroxidation and 
hepatocyte apoptosis, which are both initiators of fibrogenesis. Thus, by decreasing 
steatosis, GTE may reduce fibrosis.  
Green tea catechins may exert lipid-lowering effects by increasing lipid excretion 
from the intestines. EGCG increases the size of the mixed micelle, which may be due to 
the hydroxyl moieties on EGCG forming hydrogen bonds with phosphatidyl choline 
molecules on different micelles which causes them to coalesce. The larger micelles then 
have a decreased ability to be absorbed in the intestines [97]. EGCG has also been shown 
to interrupt pancreatic lipase activity and phospholipase A2 activity, which also decreases 
intestinal lipid absorption [98]. Decreased lipid absorption means less excess energy is 
absorbed by the body and through this mechanism green tea may reduce steatosis.  
The anti-steatotic effect of green tea may also be attributed to caffeine content 
[99]. When rats were infused intraduodenally with EGCG in the equivalent of consuming 
tea brewed from 6g of tea leaves, caffeine in the equivalent of 2 cups of coffee, or EGCG 
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plus caffeine, rats in either group that contained caffeine had reduced intestinal lipid 
absorption [99].  
GTE may also mitigate steatosis by directly increasing thermogenesis [100, 101]. 
Intact brown adipose tissue treated with caffeine in vitro used oxygen at a greater rate 
than the control tissue. Tissue treated with EGCG and caffeine used more oxygen than 
the caffeine group alone [100]. This suggests that green tea catechins and caffeine 
promote thermogenesis through unique pathways, supporting the use of green tea to 
mitigate obesity through increased energy expenditure. Human studies also support the 
role of GTE in increasing thermogenesis. When 10 participants were provided with 90 
mg catechins in addition to 50 mg of caffeine they had significantly higher resting energy 
expenditure over 24 hr compared to the trial in which they were provided a placebo. 
When they were provided with 50 mg of caffeine alone, the increase in resting energy 
expenditure was not observed [101]. 
2.7.3 Green Tea and Oxidative Stress  
GTE also alleviates oxidative stress in the liver. Ob/ob mice fed a diet containing 
0.5% or 1% GTE for 6 wk had decreased hepatic MDA and tGSH compared to the ob/ob 
control group. They also had increased hepatic Mn- and Cu/Zn-superoxide dismutase 
activity in addition to increased hepatic catalase and glutathione (GSH) peroxidase 
activity [96]. Additionally, Wistar rats fed a diet containing 60% energy from fat for 8 wk 
had significantly lower hepatic GSH and tGSH compared to the low-fat diet-fed control. 
Consuming the HFD in addition to 1% or 2% GTE resulted in a near dose-dependent 
increase in GSH and tGSH. Together, these studies suggest that GTE alleviates oxidative 
stress by maintaining endogenous antioxidant defenses [13].  
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GTE may maintain endogenous antioxidant defenses by increasing de novo GSH 
synthesis. When EGCG and buthionine sulfoximine, an inhibitor of the rate limiting 
enzyme in GSH synthesis glutamate-cysteine ligase (GCL), were incubated with HSCs, 
the GSH-raising effect of EGCG was abrogated. This suggests that the antioxidant 
function of EGCG requires de novo synthesis of GSH [102]. Supporting this hypothesis, 
EGCG increases GCL activity in activated HSCs by inducing greater gene expression of 
the catalytic subunit of GCL, GCLc [103]. GTE has also been shown to increase GCLc in 
vivo [96]. Ob/ob mice had lower hepatic GSH concentration compared to the lean control 
while there was no change in GCLc expression between obese and lean groups. This 
suggests that steatosis reduces hepatic GSH by increasing oxidative stress and not by 
inhibiting GSH biosynthesis. When ob/ob mice were fed a diet containing 1% GTE they 
had significantly greater hepatic GSH concentration than the ob/ob control and the 
increase in GSH was accompanied by increased expression GCLc to levels significantly 
higher than the obese control or the lean littermates [96]. These data suggest that green 
tea exerts it antioxidant function by modulating the expression of the rate-limiting 
enzyme GCL in GSH synthesis. Since oxidative stress plays an integral role in the 
development of fibrosis, it is possible that GTE protects against fibrosis by upregulating 
GSH.  
Furthermore, GTE has been shown to upregulate other endogenous antioxidant 
defense enzymes. Ob/ob mice consuming 1% GTE had significantly greater Mn-
superoxide dismutase, Cu/Zn-superoxide dismutase activity, GSH peroxidase and 
catalase activity compared to obese controls [96]. Similar effects were observed in Wistar 
rats that were intragastrically administered 1.8 ml ethanol every day for 4 wk and 
38 
 
provided with water containing 3 g/L GTE. Rats in the ethanol plus green tea group had 
significantly greater hepatic levels of Cu/Zn-dismutase, GSH peroxidase and catalase 
compared to the group administered ethanol without access to green tea [104]. This 
indicates that GTE increases other antioxidant defenses in addition increasing de novo 
synthesis of GSH.  
2.7.4 Green Tea and Inflammation  
Green tea also has anti-inflammatory properties [13, 105]. Sprague Dawley rats 
provided a diet containing 0.1% GTE 5 days prior to ischemia-reperfusion surgery had 
less liver injury and lower mononuclear cell infiltration 24 hr post-surgery compared to 
the positive control [105]. Animals fed GTE also had lower hepatic nuclear NFκB/DNA 
complexes and lower hepatic and plasma TNF-α mRNA [105]. Wistar rats fed a diet 
containing 60% energy from fat for 8 wk developed steatosis and liver injury, however, 
when 1% or 2% GTE was provided in addition to the HFD, animals had less steatosis as 
well as decreased NFκB binding activity in adipose and liver tissue. The decrease in 
NFκB was accompanied by a decrease in downstream expression of MCP-1 and TNF-α 
in both tissues [13].  
The mechanism by which this occurs may be dependent on the antioxidant 
activity of GTE. NFκB is a redox-sensitive transcription factor responsible for 
transcription of TNF-α [64] and MCP-1 [63] that is activated by oxidative stress [106] 
and it is inhibited by the oxidant-scavenging effects of enzymes such as GSH peroxidase 
and Mn-superoxide dismutase [107]. As mentioned previously, GTE improves hepatic 
antioxidant status and augments the activity of these antioxidant enzymes. This may lead 
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to decreased transcription of downstreatm target genes of NFκB that promote 
inflammation.  
GTE may also protect against oxidative damage associated with inflammation by 
reducing inflammatory cell infiltration. Apoptotic hepatocytes release pro-inflammatory 
mediators, which attracts Kupffer cells and neutrophils [1]. In an inflammatory 
environment, these cells produce ROS with the enzymes NADPH-oxidase and 
myeloperoxidase [50]. Ob/ob mice fed a diet containing 1% GTE had less 
myeloperoxidase protein expression and less NADPH-oxidase activity than the obese 
control [108], indicating that GTE can mitigate inflammatory cell infiltration.  
GTE may also protect against inflammation mediated by prostaglandinE2 [87]. 
The enzyme cyclooxygenase-2 is upregulated by NKκB [109] and generates 
prostaglandinE2 [110]. ProstaglandinE2 binding to its receptor then potentiates the innate 
immune response [110]. Rats fed a HFD for 8 wk in addition to 2% GTE had reduced 
protein levels and activity of cyclooxygenase-2 as well as less hepatic prostaglandinE2 
[87], indicating that GTE may prevent inflammation induced by this pathway.  
2.7.5 Green Tea and Fibrosis 
 Several studies have been completed in animals that indicate the anti-fibrogenic 
property of GTE [111-113]. Sprague Dawley rats injected intraperitoneally with a single 
dose of 500 mg/kg galactosamine to induce hepatocyte apoptosis and inflammation and 
provided with a green tea beverage (17 mg/kg/day GTE) had lower serum AST and ALT 
at 24 h post-injection compared to the positive control. Animals also had lower 
procollagen(α1)I  and TGFβ1 mRNA after 24 hr. After 14 days, there was significantly 
less staining for collagen in hepatic tissue from the GTE treatment group compared to the 
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positive control [111]. Sprague Dawley rats fed a diet containing 0.1% GTE beginning 3 
days prior to bile-duct ligation surgery had less liver injury after 24 hr  compared to the 
bile-duct ligation control, while after 3 wk animals fed the GTE diet had less fibrosis, 
reduced immunohistochemical staining for α-SMA and reduced hepatic procollagen(α1)I  
mRNA compared to the positive control. The GTE group also had less nuclear 
NFκB/DNA and AP-1/DNA complexes as well as reduced TGFβ1 and TNF-α mRNA 
[112]. Wistar rats injected with 0.5 ml/kg/day CCl4 in addition to being provided daily 
with water containing 0.1% EGCG had lower serum transaminases, less histological 
staining of collagen and lower hepatic hydroxyproline concentration as well as lower 
protein levels of α-SMA compared to the control group. The 0.1% EGCG treatment also 
resulted in lower message level and protein expression of PDGF-Rβ [113].  These studies 
indicate that oral consumption of GTE also has antifibrogenic properties. 
Green tea may prevent fibrosis by decreasing activity of NFκB. The studies 
summarized above indicate that GTE and EGCG reduce hepatic NFκB binding activity. 
NFκB promotes transcription of PDGF-Rβ [114] which promotes HSC proliferation [68]. 
NFκB also upregulates transcription of AGE-receptors [115], which upon AGE binding 
leads to increased HSC activation [74]. NFκB also initiates transcription of TNF-α which 
has an important roles in insulin resistance [28] and apoptosis [49]. Thus, by decreasing 
NFκB binding activity, GTE may protect against fibrosis through various pathways.   
Decreased TGFβ1 signaling may be another mechanism by which GTE may 
protect against fibrosis. TGFβ1 increases expression of the procollagen(α1)I gene in 
HSCs by promoting the formation of H2O2, which stimulates expression of C/EBPβ and 
promotes binding of this factor to a TGFβ1-responsive element located in the 
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procollagen(α1)I gene promoter [66]. Since GSH peroxidase is responsible for 
detoxifying intracellular H2O2 and GTE increases GSH peroxidase activity in animals 
with NAFLD [96], it is possible that GTE disrupt procollagen(α1)I transcription by 
increasing GSH peroxidase.   
Another mechanism by which GTE may protect against fibrosis is by preventing 
leptin resistance, since elevated circulating leptin is associated with advanced NAFLD 
[116]. As mentioned previously, leptin has been shown to play an integral role in fibrosis 
by increasing levels of free TGFβ1 [75], promoting further leptin expression by HSCs 
[76] and by promoting HSC proliferation [77]. Rats fed a diet containing 60% energy 
from fat had increased serum leptin compared to animals fed a diet containing 10% 
energy from fat. When rats were fed the 60% diet in addition to 1% or 2% GTE, they had 
significantly reduced levels of serum leptin [13].  Thus, it is possible that by modulating 
levels of circulating leptin, GTE prevents fibrosis.    
2.8 Conclusion 
All of these studies indicate that green tea has health-promoting properties that are 
hepatoprotective by many mechanisms. Evidence from several models and several doses 
of GTE has shown that GTE can mitigate steatosis, inflammation and oxidative stress. 
What is missing from the literature is a HFD-induced obese model that replicates the 
symptoms of obesity and exhibits disease progression of NASH into fibrosis. For that 
reason we have used a HFD-induced model of NALFD to examine the effect of GTE on 
fibrogenesis.   
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Figure 2.1 Examples of Liver Histology  
 
 
 
A) Liver tissue, 100. Thick black arrow indicates sinusoidal space. Thin black arrow 
indicates a cord of hepatocytes. Black wedges indicate space of Disse. B) Structure of the 
liver lobule and identification of the acinar zones, 10. Dotted lines show separation 
between lobules. Solid curves indicate zonal separation. Black wedges indicate zone 1 of 
the liver acinus. Black arrows indicate zone 2. White arrows with black borders indicate 
zone 3.  
  
A
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Chapter 3: Materials and Methods 
3.1 Materials 
All chemicals used for hydroxyproline determination and western blotting were 
purchased from Fisher Scientific (Waltham, MA). Dried nonfat milk was purchased from 
Big Y Foods, Inc. (Springfield, MA). Western blotting for α-SMA was performed using 
the Criterion Cell for electrophoresis (#165-6001, Bio-Rad, Hercules, CA) and the 
Criterion Blotter with Wire Electrodes for transfer (#170-4071, Bio-Rad, Hercules, CA). 
Western blotting for KLF6 was performed using the Criterion Cell for electrophoresis 
(#165-6001, Bio-Rad, Hercules, CA) and the Criterion Blotter with Plate Electrodes for 
transfer (#170-4070, Bio-Rad, Hercules, CA).  
3.2 Study Design 
The design for this study has been reported previously [13] and is summarized 
below. The study protocol was approved by the Institutional Animal Care and Use 
Committee at the University of Connecticut. Male Wistar rats (n = 63; 16 wk old) were 
purchased from Harlan Laboratories and housed individually in an environmentally 
controlled room with a 12 h light-dark cycle. After 1 wk of acclimation, rats were 
randomly assigned to 1 of 4 dietary groups for 8 wk: a low-fat diet (LFD) group 
containing no GTE, a HFD group containing no GTE, a HFD containing GTE at 1% 
(wt:wt) (HFD+1% GTE) group, or a HFD containing 2% GTE (HF+2% GTE) group. The 
LFD contained 10% energy from lard and 70% energy from carbohydrates while the 
HFD contained 60% energy from lard and 20% energy from carbohydrates. The diets 
both had 20% energy from protein (Table 3.1). Powdered GTE containing 30% (wt:wt) 
total catechins [95] was provided by Unilever BestFoods (Englewood Cliffs, NJ) and was 
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mixed into the HFD. GTE at 1% or 2% was chosen because on the basis of energy intake. 
1% and 2% GTE are estimated to be equivalent to 7 and 14 servings/d of green tea in 
humans [95] where a serving of green tea is approximately 120 ml, which is common in 
certain part of the world [15, 117]. These levels are consistent with epidemiologic 
findings suggesting that green tea consumed at ~10 servings/d may be related to lower 
levels of liver injury [16] and evidence from our previous studies show that these levels 
of GTE attenuate hepatic steatosis and injury in genetically obese mice [95]. After 8 wk 
of feeding, rats were killed under isoflurane anesthesia following 10–12 h of food 
deprivation. Liver was harvested, snap-frozen in liquid nitrogen, and stored at -80°C. 
Portions of liver were formalin fixed and embedded in paraffin for histological analysis. 
Hydroxyproline concentration, α-SMA protein expression and KLF6 nuclear protein 
expression were then determined.   
3.3 Determination of Perisinusoidal Fibrosis  
Tissue sections were deparaffinized and rehydrated using the following protocol: 
immersion in xylene for 3 min followed by immersion in xylene again for 3 min, 
immersion in 50% xylene in ethanol for 3 min, immersion in 100% ethanol for 3 min, 
immersion in 100% ethanol for 3 min, immersion in 95% ethanol for 3 min, immersion in 
70 % ethanol for 3 min and immersion in 50 % ethanol for 3 min. Slides were then rinsed 
under cold water and placed in Bouin’s fixative solution (#S129 Poly Scientific R&D, 
Bay Shore, NY) overnight at room temperature and rinsed with distilled water until the 
sections were colorless. Slides were placed in Weigert’s iron hematoxylin stain (#S216B, 
Poly Scientific R&D, Bay Shore, NY) for 10 min and subsequently rinsed with distilled 
water until clear. Slides were then placed in Gomori’s 1-step trichrome stain (#S1816, 
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Poly Scientific R&D, Bay Shore, NY) for 15 min, then rinsed with water until clear, then 
subsequently placed in 5% acetic acid for 2 min. Slides were then placed 95% ethanol for 
1 min followed by placement in 100% ethanol for 1 min then placement in xylene for 1 
min then covered with synthetic resin and coverslip. Images (100) from the 
perisinusoidal area between the central vein and the portal triads were captured using an 
Olympus IX70 (Olympus, Center Valley, PA) inverted microscope with accompanying 
software (DP2-BSW Version 2.2, Olympus, Center Valley, PA).  
3.4 Hydroxyproline  
Hydroxyproline concentration was determined using the method described by 
Reddy et al [118] with modifications. Liver (~0.2 g) was weighed and homogenized in 5 
vol of 0.9% NaCl in water using an Omni General Laboratory Homogenizer (#GLH-155, 
Omni International, Kennesaw, GA). Liver homogenate or hydroxyproline standard 
(Table 3.2A) (40 µL) were added to locking microcentrifuge tubes, followed by 10 µL of 
10 M NaOH. Samples were then autoclaved for 20 min at 120°C. After cooling to room 
temperature, 0.056 M chloramine-T solution (Table 3.2B) (450 µL) was added. Samples 
were then incubated at room temperature for 25 min, after which Ehrlich’s reagent 
(Table 3.2C) (500 µL) was added. Samples were vortexed briefly and heated in a water 
bath at 65°C for 20 min to develop the chromophore pyrrole-2-carboxylic acid from 
hydroxyproline and para-dimethylaminobenzaldehyde. 200 µL of each sample were 
loaded onto a 96 well plate, placed in the spectrophotometer (SpectraMax M2, Molecular 
Devices, Sunnyvale, CA) and optical density was measured at 550 nm. Linear regression 
between hydroxyproline concentration and optical density was performed to generate a 
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standard curve of known hydroxyproline concentrations. Data was reported as ug/g tissue 
as there was no change in liver mass between groups [13].  
3.5 α-Smooth Muscle Actin  
Liver (~0.2 g) was weighed and homogenized 1:5 (wt/wvol) using  
radioimmunoprecipitation assay (RIPA) buffer (Table 3.3A) containing protease 
inhibitor cocktail (PIC) and EDTA (#78430, Pierce Biotechnology, Rockford, IL) in a 
1:100 ratio for each the PIC and 0.5 M EDTA provided in the kit. Tissue was then 
homogenized over ice for 10 sec using an Omni General Laboratory Homogenizer 
(#GLH-155, Omni International, Kennesaw, GA). Samples were aliquoted into 
microcentrifuge tubes and centrifuged at 1,000 g for 10 min. The supernatant was 
removed and stored at -80°C until needed.   
To determine the protein concentration of samples, homogenized tissue samples 
were centrifuged at 1,000 g for 5 min and 1:100 dilutions were prepared. Protein 
concentration was then determined using the Thermo Scientific Pierce BCA Protein 
Assay Kit (#23227, Pierce Biotechnology, Rockford, IL) according to the manufacturer’s 
instructions. Linear regression between protein concentration and optical density was 
performed to generate a standard curve of known protein concentrations. The BCA assay 
for protein determination is based on the principle that the addition of the working 
reagent to any sample containing protein will cause peptides containing 3 or more amino 
acids to form a colored chelate complex with cupric ions. Bicinchoninic acid (BCA) 
reacts with the cupric cations formed from the addition of working reagent and develops 
into an intense purple-colored reaction product which results from the chelation of 2 
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molecules of BCA with 1 cuprous ion. The newly formed BCA/copper complex exhibits 
a strong linear absorbance at 562 nm with increasing protein concentrations. 
For electrophoresis, a 4-16% gradient gel was cast using a gradient gel former 
(#165-4120, Bio-Rad, Hercules, CA). polyacrylamide solutions (4% and 16%) were 
prepared simultaneously but independently. Purified water, 1.5 M Tris-HCL (pH 8.8), 
20% sodium dodecyl sulfate (SDS), 30% acrylamide/bis-acrylamide solution (#161-0158, 
Bio-Rad, Hercules, CA), tetramethylethylenediamine (TEMED) and 10% ammonium 
persulfate (APS) were combined in the appropriate volumes (Table 3.3B) and mixed 
thoroughly. The solutions were then added to individual columns of the gradient gel 
former. The solutions were then pumped out of the gradient gel formers and added to a 
Bio-Rad Criterion 26 well empty cassette (#345-9903, Bio-Rad, Hercules, CA), stopping 
the flow of gel solution ~50 mm below the well markings. 100% butanol (~3 ml) was 
added to the cassette and the gel was allowed to solidify for 60 min. After 60 min, the 
butanol was decanted and the surface of the gel was washed with deionized water and 
then dried with filter paper. While the running gel was solidifying, the same protocol as 
above was performed for the stacking gel except that 0.5 Tris-HCL (pH 6.8) was 
substituted for 1.5 M Tris-HCl (pH 8.8). After the gradient gel was solidified, the 
stacking gel solution (~ 3 ml) was pipetted to completely fill the cassette and then the 26 
well comb was inserted. After 30 min the gel was ready to be used for western blotting or 
stored in moistened paper towels in a plastic bag at 4°C until needed. 
To prepare samples for electrophoresis, homogenized samples were centrifuged at 
1,000 g for 5 min. Using the protein concentrations calculated in the previous step, the 
volume containing 100 ug of protein was removed from each sample and added to 
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locking microcentrifuge tubes. The volume was adjusted to a total volume of 15 µL with 
distilled water followed by the addition of 5 µL of 4x sample buffer (Table 3.3C). 
Samples were vortexed and placed in a 95°C water bath for 10 min and centrifuged at 
1,000 g for 60 sec.  
Samples and protein standard (#161-0374, Bio-Rad, Hercules, CA) were loaded 
onto the 4%-16% polyacrylamide gradient gel and run in running buffer (Table 3.3D) at 
20 V for 30 min followed by 100V for 60 min. Proteins were transferred in transfer 
buffer (Table 3.3E) to PVDF (#162-0177, Bio-Rad, Hercules, CA) for 60 min at 330 
milliamps. Prior to transfer, the PVDF membrane was incubated in methanol on a 
rocking platform for 2 min. Methanol was removed and PVDF was then incubated with 
transfer buffer for another 2 min.  After transfer, the membrane was blocked in blocking 
buffer (Table 3.3F) for 15 min at room temperature. The membrane was then incubated 
with rabbit anti-α-SMA antibody (#sc-130619, Santa Cruz Biotechnology, Santa Cruz, 
CA) diluted 1:500 in blocking buffer overnight at room temperature. The membrane was 
then washed 3 times in TBS-T (Tris Buffered Saline-Tween 20) (Table 3.3G) on a 
rocking platform for 5 min each. The membrane was incubated in horseradish peroxidase 
(HRP)-conjugated anti-rabbit secondary antibody (#sc-2004, Santa Cruz Biotechnology, 
Santa Cruz, CA) diluted 1:5000 in blocking buffer for 60 min at room temperature, 
followed by 3 more washings in TBS-T for 5 min each. The membrane was then 
incubated with Pierce ECL Western Blotting Substrate (#PI-32106, Pierce 
Biotechnology, Rockford, IL) and developed with a Bio-Rad ChemiDoc XRS+ System 
(Bio-Rad, Hercules, CA). Band density was then analyzed with the accompanying 
software (Image Lab version 4.0, Bio-Rad, Hercules, CA). 
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After developing, the membrane was washed for 5 min in deionized water. Then 
0.4 N NaOH was added to the membrane for 5 min, followed by washing in deionized 
water for 5 min. The membrane was then blocked for 15 min at room temperature in 
blocking buffer.  
To control for protein loading, the membrane was then incubated with mouse 
anti-β-tubulin antibody (#sc-58886, Santa Cruz Biotechnology, Santa Cruz, CA) diluted 
1:500 in blocking buffer for 60 min. Membrane was then washed 3 times for 5 min in 
TBST-T and incubated with HRP-conjugated anti-mouse secondary antibody (#sc-2005, 
Santa Cruz Biotechnology, Santa Cruz, CA) diluted 1:5000 in blocking buffer for 60 min. 
The membrane was washed 3 times for 5 min in TBS-T and incubated with Pierce ECL 
Western Blotting Substrate (#PI-32109, Pierce Biotechnology, Rockford, IL) and 
developed with a Bio-Rad ChemiDoc XRS+ System (Bio-Rad, Hercules, CA). Band 
density was then analyzed with the accompanying software (Image Lab version 4.0, Bio-
Rad, Hercules, CA). 
3.6 Kruppel-like Factor 6  
Isolation of the nuclear fraction from liver tissue was performed using the Thermo 
Scientific NE-PER Nuclear and Cytoplasmic Extraction Kit (#78835, Pierce 
Biotechnology, Rockford, IL) according to the manufacturer’s instructions with 
modifications. Cytoplasmic Extraction Reagent I (CER I) and Nuclear Extraction 
Reagent (NER) were prepared with Thermo Scientific Protease Inhibitor Cocktail (PIC) 
and EDTA (#78430, Pierce Biotechnology, Rockford, IL) in the ratio of 1:100 for each 
the PIC and 0.5 M EDTA, both of which were provided by in the kit. PIC and EDTA 
were added to prevent digestion of protein by endogenous proteases and 
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metalloproteinases. Tissue (~55 mg) was homogenized 1:10 (wt/wvol) in CER I  using an 
Omni General Laboratory Homogenizer (#GLH-155, Omni International, Kennesaw, 
GA) to cause swelling of cellular membranes. Homogenized sample (500 µL) was then 
aliquoted into microcentrifuge tubes. CER II (27.5 µL) was added to lyse cell membranes, 
allowing cytoplasmic proteins to be collected, while leaving the nucleus intact. Each sample 
was then vortexed for 5 sec. After 1 min of incubating on ice, samples were vortexed 
again for 5 sec and centrifuged at 16,000 g for 5 min at 4°C to pellet the nuclear fraction. 
Supernatant was then removed and stored as the cytoplasmic fraction. NER + PIC & 
EDTA (62.5 µL) was then added to the pellet to lyse the nuclear fraction and samples 
were vortexed for 15 sec. After incubation on ice for 10 min, samples were again 
vortexed for 15 sec. This was repeated 3 more times for a total of 40 min. Samples were 
then centrifuged for 10 min at 16,000 g at 4°C. Supernatant was removed and stored as 
the nuclear fraction.  
After nuclear extraction, 1:10 dilutions of each nuclear fraction sample were 
prepared. Sample protein concentration was then determined using the Thermo Scientific 
Pierce BCA Protein Assay Kit (#23227, Pierce Biotechnology, Rockford, IL) according 
to the manufacturer’s instructions and according to the principle described above. 
Using the protein concentrations determined from the BCA assay, the volume of 
sample containing 50 ug was removed from nuclear extract stocks and added to locking 
microcentrifuge tubes. The volume was adjusted to 15 µL with distilled water followed 
by the addition of 5 µL of 4x sample buffer. Samples were vortexed and placed in a 95°C 
water bath for 10 min and centrifuged at 1,000 g for 60 sec.  
51 
 
For electrophoresis, a 10% polyacrylamide slab gels were prepared. For the 
running gel, purified water, 1.5 M Tris-HCl (pH 8.8), 20% SDS and 30% acrylamide/bis-
acrylamide solution, TEMED and 10% APS were combined in the appropriate volumes 
(Table 3.3B) and mixed thoroughly. The solution (~13 ml) was then pipetted gently into 
a Bio-Rad Criterion 26 well empty cassette (#345-9903, Bio-Rad, Hercules, CA) until 
~50 mm below the well markings. 100% butanol (~3 ml) was then pipetted into the 
cassette. After 60 min, the butanol was decanted and the surface of the gel was washed 
gently with deionized water then dried with filter paper. While the running gel was 
solidifying, the same protocol as above was performed for the stacking gel except that 1.5 
M Tris-HCl (pH 8.8) was replaced with 0.5 M Tris-HCL (pH 6.8). The stacking gel 
solution (~3 ml) was then pipetted into the cassette until full and then the 26 well comb 
was inserted. After 30 min the gel was ready to be utilized for electrophoresis or stored in 
moistened paper towels in a plastic bag at 4°C until needed.  
Samples and protein standard (#161-0374, Bio-Rad, Hercules, CA) were loaded 
onto the 10% slab polyacrylamide gel and run at 100 V for 90 min in running buffer. 
Proteins were transferred in transfer buffer to PVDF (#162-0177, Bio-Rad, Hercules, CA) 
for 40 min at 100 V in 4°C. Prior to transfer, the PVDF membrane was incubated in 
methanol on a rocking platform for 2 min. Methanol was then removed and PVDF was 
incubated in transfer buffer for another 2 min.  After transfer, the membrane was blocked 
in blocking buffer for 60 min at room temperature. Incubation with rabbit anti-KLF6 
antibody (#sc-7158; Santa Cruz Biotechnology, Santa Cruz, CA) diluted 1:200 in 
blocking buffer for 60 min at room temperature was followed by 3 washings in TBS-T 
for 5 min each. The membrane was incubated with HRP-conjugated anti-rabbit secondary 
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antibody (#162-0177, Bio-Rad, Hercules, CA) diluted 1:1000 in blocking buffer for 60 
min at room temperature, followed by 3 washings in TBS-T for 5 min each. The 
membrane was incubated with Pierce ECL Western Blotting Substrate (#PI-32109, Pierce 
Biotechnology, Rockford, IL) and developed with a Bio-Rad ChemiDoc XRS+ System 
(Bio-Rad, Hercules, CA). Band density was then analyzed with the accompanying 
software (Image Lab version 4.0, Bio-Rad, Hercules, CA). 
After developing, the membrane was incubated in stripping buffer (Table 3.3H) 
for 5 min. Then the buffer was replaced with new stripping buffer for another 5 min. 
After stripping, the membrane was washed 2 times for 10 min each in PBS, followed by 
washing in TBS-T 2 times for 5 min each. The membrane was then blocked at room 
temperature for 60 min in blocking buffer.  
To control for protein loading, the membrane was incubated in mouse anti-
TATA-box binding protein antibody (#AB818, Abacam, Cambridge, MA) diluted 
1:10,000 diluted in blocking buffer for 2 h followed by washing 3 times for 5 min in 
TBST-T and incubation with HRP-conjugated anti-mouse secondary antibody diluted 
1:1000 in blocking buffer for 60 min. The membrane was washed 3 times for 5 min in 
TBS-T and incubated with Pierce ECL Western Blotting Substrate (#PI-32109, Pierce 
Biotechnology, Rockford, IL) and developed with a Bio-Rad ChemiDoc XRS+ System 
(Bio-Rad, Hercules, CA). Band density was then analyzed with the accompanying 
software (Image Lab version 4.0, Bio-Rad, Hercules, CA). 
3.7 Statistical Analysis 
Data (means ± SE) were analyzed using GraphPad Prism (Version 5.02; 
GraphPad Software, Inc.; San Diego, CA, USA). One-way ANOVA with Newman-
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Keuls’s post-test was used to evaluate the differences between group means. Regression 
analysis was used to evaluate associations between variables. Analyses were considered 
statistically significant at an α-level of P < 0.05.  
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Table 3.1 Composition of Experimental Diets1 
 
Low Fat Diet (D12450B) 
  
High Fat Diet (D12492) 
  
Macronutrient Composition 
% Total Energy   
Macronutrient Composition 
% Total Energy    
Protein 20 Protein 20 
Carbohydrate 20 Carbohydrate 70 
Fat 10 Fat 60 
Fat Composition 
% Total Fat   
Fat Composition 
% Total Fat  
Saturated 22.7  Saturated 32.0 
Monounsaturated 29.9  Monounsaturated 35.9 
Polyunsaturated  47.4  Polyunsaturated 32.0 
Ingredients (g/kg)   Ingredients (g/kg)   
Casein  200 Casein  200 
L-cystine 3 L-cystine 3 
Corn Starch 315 Corn Starch 0 
Maltodextrin 35 Maltodextrin 125 
Sucrose 350 Sucrose 68.8 
Cellulose 50 Cellulose 50 
Soybean Oil 25 Soybean Oil 25 
Lard 20 Lard 245 
Mineral Mix 10 Mineral Mix 10 
DiCalcium Phosphate 13 DiCalcium Phosphate 13 
Calcium Carbonate 5.5 Calcium Carbonate 5.5 
Potassium Citrate 16.5 Potassium Citrate 16.5 
Vitamin Mix 10 Vitamin Mix 10 
Choline Bitatarate 2 Choline Bitatarate 2 
1Research Diets, Inc. New Brunswick, NJ 
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Table 3.2 Reagents for Hydroxyproline Determination 
 
A. Hydroxyproline Standard 
5 mg hydroxyproline   
5 ml H2O 
 
B. Chloramine-T Solution: 
0.056 M Chloramine-T trihydrate 
10% propanol 
Prepared in acetate-citrate buffer 
 
C. Acetate-Citrate Buffer (pH 6.5):  
880 mM sodium acetate trihydrate 
220 mM citric acid 
850 mM NaOH 
1.2% glacial acetic acid 
Prepared in H2O 
 
D. Ehrlich’s Reagent: 
1M para-dimethylaminobenzaldehyde  
Prepared in 2:1 n-propanol/60% perchloric acid 
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Table 3.3 Reagents for Western Blotting 
 
A. RIPA Buffer 
50 mM Tris-HCl, pH 7.4  
150 mM NaCl 
0.1% SDS 
0.5% Sodium Deoxycholate 
1% NP-40 
 
 
C. 4x Sample Buffer Stock 
10% SDS (w/v) 
.25 M Tris HCl (pH 6.8) 
32% (v/v) glycerol 
0.017% bromophenol blue 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B. Gel Preparation       
 
 
 
4% Gel 10% Gel 16% Gel 
Gradient 
Stacking 
Gel 
Slab 
Stacking 
Gel 
% Acrylamide  4 10 16 3 5 
Final Volume Desired (ml)  7 3.75 7 3 5  
H2O (ml) 4.24 6.09 1.44 1.92 2.86 
1.5 M Tris-HCl, pH 8.8  (ml) 1.75 3.75 1.75 0 0 
0.5 M Tris-HCl, pH 6.8 (ml) 0 0 0 0.75 1.25 
20% SDS  (ml) 0.04 0.08 0.04 0.015 0.03 
30% Acrylamide/Bis (ml) 0.93 5 3.73 0.3 0.83 
10% (w/v) APS (ml) 0.04 .08 0.04 0.015 0.03 
TEMED (ml) 0.004 .01 0.004 0.003 0.005 
D. Running Buffer 
50 mM Tris-HCl 
380 mM Glycine 
0.1% SDS 
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E. Transfer Buffer 
50 mM Tris-HCl 
380 mM Glycine 
0.1% SDS 
10% Methanol 
F. Blocking Buffer 
5% Dry Non-fat Milk 
Prepared in TBS-T 
 
 
G. TBS-T 
100 mM Tris-HCl  
0.9% NaCl  
0.1% Tween-20 
 
H. Stripping Buffer (pH 2.2) 
200 mM Glycine 
3.5 mM SDS 
1% Tween-20 
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Chapter 4: Results 
4.1 Body Weight, Insulin Resistance,  Liver Injury and Oxidative Stress 
The effects of GTE on body composition, energy intake, serum AST, serum ALT, 
tGSH, nuclear NFκB activity [13], plasma glucose levels, plasma insulin levels and 
insulin resistance [87] have been reported previously.  In brief, after the 8 wk dietary 
intervention, the HFD group had 30% greater adipose mass (P < 0.001) and gained 
significantly more weight (P < 0.01) than the LFD group. The body weight of rats in 
HFD+1% GTE and HFD+2% GTE was not different than body weight of rats fed the 
LFD. The difference in body weight between the groups occurred without a significant 
change in energy intake (P > 0.05, Table 4.1). The HFD group was more insulin resistant 
as calculated by HOMA-IR (GlucoseInsulin/22.5) compared to the LFD group. 
HFD+1% GTE and HFD+2% GTE groups had HOMA-IR comparable to the LFD group 
(Table 4.1). These data support that GTE mitigates weight gain and insulin resistance, 
independent of any changes in energy intake. Plasma ALT in the HFD group was nearly 
double that of the LFD group while ALT in the HFD+GTE 1% or 2% was similar to the 
LFD group. (P <0.0001, Table 4.1). The HFD group also had nearly double plasma AST 
levels compared to the LFD group. The HFD+GTE 1% group had 18% lower plasma 
AST and the HFD+GTE 2% group had 32% lower AST compared to HFD (P = 0.001, 
Table 4.1). The HFD group had 32% lower concentrations of tGSH compared to the LFD 
group. GTE treatment near dose-dependently increased tGSH to the extent that tGSH in 
the HFD+GTE 2% group was significantly higher than the HFD group (P<0.0001, Table 
4.1).  
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4.2 Perisinusoidal Fibrosis and Hepatic Hydroxyproline  
 Hepatic fibrosis resulting from NAFLD begins in the perisinusoidal area between 
the hepatic cords [25] (Figure 2.5.1A). Visualization of liver sections following 
trichrome staining showed evidence of collagen deposition within the perisinusoidal 
space of rats in the HFD group, whereas rats in the LFD group as well as in the 
HFD+GTE 1% and HFD+2% GTE groups had less histological evidence of 
perisinusoidal fibrosis (Figure 4.2.1).  
The occurrence of hydroxyproline is exclusive to connective tissue where it 
occupies the Y position of the glycine-X-Y repeating peptide of collagen [119]. Hepatic 
hydroxyproline concentrations were higher in the HFD group compared to the LFD group 
(P < 0.05, Figure 4.2.2). HFD+1% GTE and HFD+2% GTE groups had less 
hydroxyproline than the HFD group and had hydroxyproline not different than the LFD 
group. Thus, GTE prevents hepatic fibrosis and mitigates hepatic collagen accumulation 
in HFD-induced NAFLD. Serum AST released by damaged hepatocytes has been 
identified as an indicator of the extent of hepatic fibrosis [26]. Regression analysis of 
AST and hepatic hydroxyproline indicates that AST positively correlated with hepatic 
hydroxyproline concentrations (r = 0.30, P < 0.05, Figure 4.2.3A), suggesting that 
hepatocyte injury is associated with hepatic collagen deposition. Additionally, tGSH was 
inversely correlated with hepatic hydroxyproline concentrations (r = -0.33, P = 0.01, 
Figure 4.2.3B), suggesting that greater oxidative stress results in greater hepatic collagen 
deposition. 
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4.3 Hepatic α-SMA  
 Rats fed the HFD had 37% greater hepatic α-SMA expression compared to the 
LFD group (P < 0.01, Figure 4.3.1). α-SMA expression in the HFD+1% GTE group was 
higher (P < 0.01) than that from the LFD group and not different from that of the HFD 
group. However, α-SMA expression of the HFD+2% GTE group was 31% less than that 
of the HFD group and was not statistically different from LFD group. These data 
indicates that greater dietary levels of GTE may mitigate HSC activation. Because HSCs 
deposit collagen during hepatic fibrosis [58], the correlation between α-SMA and 
hydroxyproline concentration was analyzed. Consistent with the etiology of hepatic 
fibrosis [1], α-SMA protein expression was correlated to hydroxyproline concentrations 
(r = 0.43, P < 0.001, Figure 4.3.2A). Serum AST was also correlated with α-SMA 
expression (r = 0.30, P < 0.05, Figure 4.3.2B) suggesting that greater liver injury induces 
greater HSC activation. Hepatic tGSH was inversely related to α-SMA expression (r = -
0.31, P < 0.05, Figure 4.3.2C), suggesting that greater oxidative stress may promote 
activation of HSCs. Regression analysis also indicates that NFκB activity correlated 
positively (r = 0.33, P < 0.05, Figure 4.3.2D) with α-SMA expression, indicating that 
inflammation associated with greater NFκB nuclear binding activity  may be associated 
with greater  HSC activation.  
4.4 Hepatic Nuclear KLF6  
 KLF6 is a transcription factor that upregulates important fibrogenic proteins such 
as pro-collagen(α1)I and TGFβ1 [11] and is induced by oxidative stress [84]. Nuclear 
KLF6 protein was 77% higher in the HFD group compared to the LFD group (Figure 
4.4). Nuclear protein levels of KLF6 in the HFD+1% GTE and HFD+2% GTE groups 
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were higher than that of the LFD group (P < 0.01) and were not significantly different 
from the HFD group. This suggests that nuclear translocation of KLF6 is unaffected by 
GTE. 
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Table 4.1 Body Composition, Energy Intake, and Biochemical Markers of NAFLD from 
rats fed a LFD, HFD, HFD+1% GTE or HFD+ 2% GTE for 8 wk1  
 LFD  HFD HF + 1% GTE  
HF + 2% 
GTE      P  
2Initial Body Weight (g) 369.0 ± 5.1  373.7 ± 4.7  370.2 ± 4.5  372.3 ± 4.2  >0.05  
2Final Body Weight (g) 512.8 ± 12.4a  572.2 ± 11.5b  512.7 ± 13.3a  537.6 ± 11.2a  <0.01  
2Liver Mass (g)  14.1 ± 0.8  14.4 ± 0.3  13.2 ± 0.7  12.8 ± 0.4  >0.05  
2Energy Intake (kcal/d)  90.2 ± 2.5  90.8 ± 1.7  85.4 ± 4.2  86.6 ± 2.0  >0.05  
3Plasma Glucose 
(mmol/L) 13.4 ± 0.7
 12.6 ± 0.9 11.8 ± 0.5 11.7 ± 0.3 >0.05 
3Plasma Insulin 
(ng/ml)  2.6 ± 0.3
a
  3.7 ± 0.5b  2.3 ± 0.2a  2.1 ± 0.3a  <0.01  
3HOMA-IR  34.1 ± 4.5a  50.2 ± 8.3b  29.6 ± 2.9a  26.5 ± 4.0a  <0.05  
2Serum AST (U/L)  54.6 ± 3.8a 98.6 ± 9.9b 80.7 ± 7.5bc 67.1 ± 4.8ac <0.001 
2Serum ALT (U/L)  28.8 ± 2.3a 57.1 ±7.2b   35.5 ± 2.8a 34.9 ± 1.5a <0.001 
2tGSH (nmol/mg tissue)  3.7 ± 0.2a 2.8 ± 0.1c 3.1 ± 0.1bc 3.3 ± 0.2b <0.001 
2NFκB p65 binding 
activity (%LF) 100 ± 12
b
 224 ± 24a 139 ± 37b 92 ± 9b <0.001 
 
1Data are means ± SE, n = 15–16. Labeled means groups without a common letter differ, 
P < 0.05. GTE, green tea extract; HFD, high-fat diet; HFD+1% GTE, high-fat diet 
containing 1% green tea extract; HFD+2% GTE, high-fat diet containing 2% green tea 
extract; LFD, low-fat diet; HOMA-IR, Homeostatic Model Assessment of Insulin 
Resistance; AST, aspartate aminotransferase; ALT, alanine aminotransferase; tGSH, 
hepatic total glutathione. 
2Data previously reported by Park et al [13] 
3Data in preparation for publication by Chung et al [87] 
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Figure 4.2.1 Histological Evidence of Perisinusoidal Fibrosis from the liver of rats fed a 
LFD, HFD, HFD+1% GTE or HFD+ 2% GTE for 8 wk1 
 
Gomori’s trichrome stain, 100. Arrows indicate the location of collagen deposition. A) 
Sample liver section from the LFD group. B) Sample liver section from the HFD group.  
C) Sample liver section from the HFD+1% GTE group. D) Sample liver section from the 
HFD+2% GTE group.  
1Abbreviations: GTE, green tea extract; HFD, high-fat diet; HFD+1% GTE, high-fat diet 
containing 1% green tea extract; HFD+2% GTE, high-fat diet containing 2% green tea 
extract; LFD, low-fat diet 
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Figure 4.2.2 Concentration of Hepatic Hydroxyproline measured from the liver of rats 
fed a LFD, HFD, HFD+1% GTE or HFD+ 2% GTE for 8 wk1  
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1Data are means ± SE, n = 15–16. Labeled means columns without a common letter 
differ, P < 0.05. Abbreviations: GTE, green tea extract; HFD, high-fat diet; HFD+1% 
GTE, high-fat diet containing 1% green tea extract; HFD+2% GTE, high-fat diet 
containing 2% green tea extract; LFD, low-fat diet. 
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Figure 4.2.3 Correlations of Liver Injury and Oxidative Stress to Hydroxyproline 
measured from rats fed a LFD, HFD, HFD+1% GTE or HFD+ 2% GTE for 8 wk1 
 
 
 
 
 
 
 
 
 
A) There is a significant positive correlation between AST and hydroxyproline 
concentration. B) There is a significant inverse correlation between tGSH and 
hydroxyproline concentration.  
1r represents the Pearson correlation coefficient, P <0.05. Abbreviations: GTE, green tea 
extract; HFD, high-fat diet; HFD+1% GTE, high-fat diet containing 1% green tea extract; 
HFD+2% GTE, high-fat diet containing 2% green tea extract; LFD, low-fat diet; α-SMA, 
alpha-smooth muscle actin; AST, aspartate aminotransferase; tGSH, hepatic total 
glutathione. 
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Figure 4.3.1 Hepatic α-SMA Protein Expression measured from the liver of rats fed a 
LFD, HFD, HFD+1% GTE or HFD+ 2% GTE for 8 wk1  
 
                                                    
 
 
 
   
 
 
 
1Data are means ± SE, n = 15–16. Labeled means columns without a common letter 
differ, P < 0.05. Abbreviations: GTE, green tea extract; HFD, high-fat diet; HFD+1% 
GTE, high-fat diet containing 1% green tea extract; HFD+2% GTE, high-fat diet 
containing 2% green tea extract; LFD, low-fat diet.  
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Figure 4.3.2 Correlations of α-SMA and biomarkers of NASH or fibrosis measured from 
rats fed a LFD, HFD, HFD+1% GTE or HFD+ 2% GTE for 8 wk1 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A) There is a significant positive correlation between α-SMA expression and hepatic 
hydroxyproline concentration. B) There is a significant positive correlation between AST 
and α-SMA protein expression. C) There is a significant inverse correlation between 
tGSH and α-SMA protein expression. D)  There is a significant positive correlation 
between NFκB activity and α-SMA protein expression.  
1r represents the Pearson correlation coefficient, P <0.05. Abbreviations: GTE, green tea 
extract; HFD, high-fat diet; HFD+1% GTE, high-fat diet containing 1% green tea extract; 
HFD+2% GTE, high-fat diet containing 2% green tea extract; LFD, low-fat diet; α-SMA, 
alpha-smooth muscle actin; AST, aspartate aminotransferase; tGSH, hepatic total 
glutathione; NFκB, nuclear factor kappa-light-chain-enhancer of activated B cells. 
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Figure 4.4 Hepatic Nuclear Protein Expression of KLF6 measured from the liver of rats 
fed a LFD, HFD, HFD+1% GTE or HFD+ 2% GTE for 8 wk1  
                                             
 
 
 
 
 
 
 
1Data are means ± SE, n = 15–16. Labeled means columns without a common letter 
differ, P < 0.05. Abbreviations: GTE, green tea extract; HFD, high-fat diet; HFD+1% 
GTE, high-fat diet containing 1% green tea extract; HFD+2% GTE, high-fat diet 
containing 2% green tea extract; LFD, low-fat diet. 
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Chapter 5: Discussion 
This thesis provides the first evidence in a HFD-induced model of NASH that 
GTE protects against fibrosis. GTE at 1% and 2%, which is the equivalent to 7 and 14 
cups/d of green tea in humans, prevented hepatic fibrosis that was otherwise induced by a 
HFD as evidenced by a reduction in histologic staining towards collagen and by direct 
evidence showing that GTE at either level normalized hepatic hydroxyproline 
concentrations to that of controls fed a LFD.  In further support, rats in the HFD + 2% 
GTE group had less HSC activation as suggested by lower protein expression of α-SMA 
whereas GTE had no effect on nuclear accumulation of KLF6, which was otherwise 
increased by a HFD. Collectively, these findings suggest that GTE inhibits the 
development of fibrosis by suppressing HSC activation, but that the mechanism is 
independent of the transcriptional effects of KLF6 that are known to promote liver 
fibrosis [10, 11].   
The underlying hypothesis of this thesis, that GTE would protect against fibrosis 
otherwise induced by a HFD, was based on existing evidence showing that GTE or 
EGCG protects against chemically-induced [111, 113, 120, 121]  or surgically-induced 
[112, 122] fibrosis. This thesis indicates that consumption of a HFD leads to 
perisinusoidal fibrosis and that GTE mitigates this effect. This observation was verified 
by hydroxyproline quantification, since hepatic hydroxyproline concentrations were 
elevated in the HFD group and were significantly lower in both GTE treatment groups.  
Western blot analysis of α-SMA protein expression indicated that the HFD 
increased HSC activation, while HSC activation was mitigated by GTE at 2% (Figure 
4.3.1). HSCs are the primary cell types responsible for collagen deposition during fibrosis 
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[58] and the role of greater HSC activation in fibrosis was supported in thesis by 
regression analysis that indicated a positive relation between α-SMA and hydroxyproline 
(Figure 4.3.2A). Regression analysis also indicated that there was a positive relation 
between plasma AST activity and α-SMA expression (Figure 4.3.2B) as well as an 
inverse relation between tGSH and α-SMA expression (Figure 4.3.2C). These 
correlations suggest that greater liver injury and greater oxidative stress are associated 
with increased HSC activation and are consistent with reports that HSCs are activated by 
liver injury and oxidative stress [61], since damaged hepatocyte mitochondria release 
AST [24] and ROS [40] under conditions associated with NAFLD. Several studies in 
chemically and surgically-induced models of fibrosis, in addition to the model used in 
this thesis, have reported that GTE or EGCG treatment prevents α-SMA protein 
expression in addition to preventing collagen deposition in experimental fibrosis [112, 
113, 120-122]. Because HSCs are integral in collagen deposition during hepatic fibrosis, 
GTE may prevent fibrosis by preventing HSC activation. 
GTE may mitigate HSC activation and fibrosis by increasing endogenous 
antioxidant defenses. Increased hepatic GSH was observed in rats fed a HFD containing 
1% and 2% GTE for 8 wk [13] and in rats administered ethanol in addition water 
containing GTE [123] compared to their respective controls. Rats administered ethanol in 
addition to water containing GTE also had greater hepatic protein levels of Cu/Zn-
superoxide dismutase, GSH peroxidase and catalase. These studies indicate that GTE 
increases antioxidant defenses and that this may protect against fibrosis. 
Since antioxidant enzymes scavenge ROS involved in the signaling cascade that 
leads to increased nuclear binding activity of the redox sensitive transcription factor 
71 
 
NFκB [107] and NFκB promotes the transcription of several genes that initiate and 
perpetuate fibrosis [63, 64, 114], GTE-mediated increases in antioxidant enzymes may 
prevent fibrosis. One mechanism by which this may occur is by preventing HSC 
proliferation. Regression analysis of data regarding hepatic NFκB activity reported 
previously [13] and data on α-SMA reported in this thesis showed that NFκB activity was 
positively correlated to α-SMA (Figure 4.3.2D). NFκB is responsible for the 
transcription of PDGF-Rβ [114]. PDGF is expressed by Kupffer cells [69] and promotes 
HSC proliferation [68]. Since green tea polyphenols reduce hepatic NFκB binding 
activity [13, 112, 114], it is possible that GTE prevents fibrosis by mitigating HSC 
proliferation. GTE may also prevent fibrosis by preventing expression of other 
downstream targets of NFκB that contribute to fibrogenesis. In addition to PDGF-Rβ, 
NFκB upregulates TNF-α [64] which promotes mitochondrial dysfunction [41] and 
hepatocyte apoptosis [49] leading to fibrosis. NFκB also upregulates MCP-1 [63], which 
is a potent chemoattractant for inflammatory cell types and activator of HSCs [1]. Thus, 
by reducing transcription of these cytokines, GTE may further protect against fibrosis.   
GTE-mediated increases in endogenous antioxidant defenses may also prevent 
fibrosis by interrupting other pro-fibrogenic signaling cascades dependent on ROS. 
Leptin and TGFβ1 both promote fibrosis by increasing expression of procollagen(α1)I 
and use H2O2 as a second messenger upon binding to their receptor [66, 124]. Since GSH 
peroxidase is responsible for detoxifying intracellular H2O2 and GTE increases GSH 
peroxidase activity in animals with NAFLD [104], it is possible that GTE disrupts 
procollagen(α1)I transcription by increasing hepatic GSH peroxidase.  This effect of GTE 
may also explain why GTE at 1% prevented hepatic collagen accumulation without 
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affecting HSC activation. While GTE at 1% did not prevent HSC activation, it may have 
prevented collagen deposition by this cell type by preventing the signaling cascades that 
lead to procollagen(α1)I transcription by interrupting TGFβ1 and leptin signaling.   
GTE-mediated increases in endogenous antioxidant defenses may also protect 
against fibrosis by preventing the formation of the lipid peroxidation end products 4-HNE 
and MDA which are hepatotoxic in that they bind to mitochondrial DNA [53], nuclear 
DNA [54] and proteins [55], which may result in inactivation of important enzymes [27] 
and lead to fibrosis [1]. 4-HNE and MDA have also been directly implicated in HSC 
expression of procollagen(α1)I [62, 125]. Previous work in the animals studied in this 
thesis indicates that hepatic MDA was lower in rats fed a HFD in addition to 1% or 2% 
GTE compared to the HFD control [87]. Furthermore, rats that underwent bile-duct 
ligation surgery provided with 50 mg/kg/day of GTE via intragastric administration 
beginning three days prior to surgery had less immunohistological staining for 4-HNE 
and α-SMA as well as less histological staining of collagen after 17 days compared to the 
positive bile-duct ligation control [122]. Thus, these studies indicate that GTE may 
prevent fibrosis by preventing the harmful effects of lipid peroxidation and formation of 
its end products.    
Another mechanism by which GTE may protect against fibrosis is by preventing 
hyperleptinemia. Leptin plays an integral role in fibrosis by increasing levels of free 
TGFβ1 [75], promoting HSC proliferation [77] and by promoting further leptin 
expression by HSCs [76]. Previous work in this animal model from our lab indicates that 
consuming 1% or 2% GTE in addition to the HFD decreases circulating leptin [13].  
Thus, it is possible that by modulating levels of circulating leptin, GTE prevents fibrosis.    
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GTE may also protect against fibrosis by preventing obesity and steatosis. 
Previous work in this model shows that GTE prevents adiposity and steatosis induced by 
the HFD, independent of energy intake [13]. This may be the result of GTE-mediated 
elevation in the transcription of the gene for carnitine palmitoyl transferase-1. Carnitine 
palmitoyl transferase-1 is involved in β-oxidation of free fatty acids [38] and animals fed 
the HFD+1% GTE and HFD+2% GTE has significantly greater mRNA for this enzyme 
compared to the LFD and HFD controls [87]. By increasing β-oxidation, GTE may 
prevent obesity and steatosis independent of energy intake.  
KLF6 upregulates procollagen(α1)I transcription as well as transcription TFGβ1 
and its receptors [10, 11] and expression of this transcription factor is induced by 
oxidative stress [83]. Since GTE prevents hepatic fibrosis and mitigates oxidative stress, 
it was hypothesized that this may be due, in part, to decreased nuclear levels of the 
transcription factor KLF6. Contrary to the hypothesis, we found that although HFD 
feeding increased nuclear KLF6, GTE at either dose had no effect on nuclear 
accumulation of this transcription factor. Because transcriptional upregulation of pro-
fibrogenic genes regulated by KLF6 is dependent on cooperation with the transcription 
factor Sp1 [126], interruption in Sp1 activity may prevent KLF6 from upregulating its 
target genes. In fact, EGCG has been shown to decrease expression, DNA binding 
activity and transactivation activity of Sp1 [127, 128]. If Sp1 nuclear activity is inhibited 
by GTE in HFD-induced fibrosis, then nuclear translocation of KLF6 may still occur, 
while KLF6 would be unable to promote transcription of its target genes. Thus, future 
studies should consider examining nuclear translocation of Sp1 in this model as well as to 
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perform co-immunoprecipitation experiments to determine if KLF6 and Sp1 are 
interacting in the nuclei of hepatic cells in the GTE treatment groups.  
KLF6 contributes to upregulation procollagen(α1) in fibrosis [11] and this thesis 
reports that GTE prevented hepatic collagen accumulation that was not accompanied by a 
reduction in KLF6 nuclear accumulation. This necessitates the identification of other 
contributors to collagen deposition that may have been affected by GTE. Interrupting 
TGFβ1 and leptin mediating signaling that initiates procollagen(α1)I transcription may be 
one mechanism by which GTE prevents collagen accumulation independent of KLF6. As 
previously mentioned, these signaling cascades are depending on H2O2 [66, 124]. GTE 
increases endogenous GSH peroxidase [104], which may interrupt this signaling cascade 
resulting in decreased collagen transcription. Additionally, activated HSCs are the 
primary cell type responsible for collagen deposition during fibrosis and this thesis has 
shown that supplementation of GTE at 2% resulted in lower HSC activation. Thus the 2% 
GTE treatment may have limited collagen deposition by preventing HSC activation, a 
mechanism independent of KLF6.  
A strength of this study is that the HFD-induced NAFLD model replicates certain 
aspects associated with of fibrosis are not present in other models of fibrosis. The HFD-
induced model of fibrosis exhibits hyperleptinemia, hyperlipidemia and insulin resistance 
[13, 87]. These components are absent in other commonly used model of fibrosis such as 
CCl4-injection and methionine choline deficiency [129, 130]. As a result of using the 
HFD model, it is possible to determine the effect of GTE on these parameters in the 
context of fibrosis and creates a better understanding of the therapeutic potential of GTE. 
75 
 
 The difficulty in diagnosing NAFLD [2] suggests that an emphasis should be 
placed on prevention of this condition over treatment. Thus, another strength of this study 
is it that it supports further investigation of increased green tea consumption in humans as 
a therapy to prevent fibrosis. Because of the high prevalence of NAFLD in obese 
individuals [3] and the rise in obesity over the past two decades [131], identifying a 
simple therapy that mitigates the progression of NAFLD may protect the health of 
millions of individuals. 
A limitation of this model is that rats fed a HFD to induce NAFLD develop 
steatosis in a manner different from its pathogenesis in humans. Studies from our lab on 
this model indicates that animals fed the HFD had significantly lower circulating free 
fatty acids, total cholesterol and triglycerides, regardless of the green tea treatment. HFD-
fed animals also had lower expression of genes involved in de novo lipogenesis compared 
to the LFD which was independent of the GTE treatments [87]. NAFLD in humans is 
accompanied by increased serum lipids as well as increased de novo lipogenesis [27] 
indicating this model does not perfectly replicate NAFLD in humans. Despite the 
decreased serum lipids and de novo lipogenesis, animals in this study still developed 
steatosis. This is likely the result of increased hepatic triglyceride synthesis, since animals 
in the HFD groups had greater gene expression of the enzyme diglyceride 
acyltransferase-2 [87].   
Also, despite consuming the same amount of calories as the LFD group and the 
green tea treatment groups, animals in the HFD group had significantly greater body 
weight. As mentioned previously, animals in the green tea treatment groups had greater 
expression of carnitine palmitoyl transferase-1 which is involved in β-oxidation and this 
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may account for the difference in body weight. However, animals in the LFD and HFD 
groups did not have significantly different levels of carnitine palmitoyl transferase-1 and 
yet the HFD still weighed significantly more than the LFD group. This may be explained 
in part by the observation that animals in the HFD group has significantly lower blood 
lipids compared the LFD. This suggests that there is less lipolysis of fatty acids from 
adipose tissue and less transport of fatty acids out of the liver. This may result in 
increased accumulation of fat in these sites of lipid storage and thus increase adiposity 
without a change in energy intake or β-oxidation.  
Another limitation of this study is that it cannot distinguish at which stage in the 
progression of NAFLD that GTE exhibits its anti-fibrogenic effects. It is possible that 
GTE mitigates fibrosis by mitigating precursor events such as insulin resistance and 
steatosis. Previous work in this model shows that GTE prevents insulin resistance, 
hepatic lipid accumulation, transcription of pro-inflammatory cytokines and oxidative 
stress as indicated by increased hepatic GSH [13, 87], thus GTE may be mitigating 
NAFLD at any stage. This prevention study should be complimented by treatment studies 
in order to more fully understanding the therapeutic potential of green tea, since early 
stages of NAFLD are difficult to diagnose [2].   
Lastly, in order to better understand the mechanism by which GTE prevents 
fibrosis, our protein expression experiments should be complimented by gene expression 
experiments. Measuring hepatic mRNA levels of α-SMA and procollagen(α1)I would 
provide insight into how GTE modulates the expression of these proteins. It would also 
be valuable to measure mRNA levels of TGFβ1 since this cytokine plays an important 
role in collagen deposition by HSCs [66].  
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 In conclusion, Wistar rats fed a diet containing 60% fat for 8 wk develop obesity, 
insulin resistance and leptin resistance as well as steatosis and NASH. We have shown 
for that animals fed this diet over 8 wk also develop fibrosis. Using this model we have 
also shown that consuming GTE in addition to the HFD mitigates fibrogenesis by 
reducing HSC activation and thus hepatic collagen deposition and this occurs 
independent of nuclear KLF6 accumulation. The results of this study are consistent with 
the findings of others using various other models of fibrosis. Our study is unique in that it 
indicates that GTE has anti-fibrogenic properties under conditions associated obesity. 
Furthermore, this study supports investigating increased consumption of green tea in 
humans as a therapy for preventing the development of fibrosis associated with NAFLD.   
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